mitomycin and Postoperative Complications studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.

Research Excerpts

Excerpt	Relevance	Reference
"To determine whether adjunctive mitomycin C (MMC) or amniotic membrane transplantation (AMT) improve the outcomes of Ahmed glaucoma valve (AGV) implantation."	9.22	Adjunctive Mitomycin C or Amniotic Membrane Transplantation for Ahmed Glaucoma Valve Implantation: A Randomized Clinical Trial. ( Doozandeh, A; Ghahari, E; Mahboobipour, H; Pakravan, M; Yazdani, S, 2016)
"The authors conducted a study to evaluate the effects and the safety of locally applied mitomycin C (MMC) on epidural fibrosis after microendoscopic discectomy (MED)."	9.17	Inhibition of epidural fibrosis after microendoscopic discectomy with topical application of mitomycin C: a randomized, controlled, double-blind trial. ( Cao, X; Hong, X; Liu, L; Sui, T; Wu, X, 2013)
"To compare the long-term outcome of pterygium surgery and the long-term effect on endothelial counts after mitomycin C (MMC) or limbal conjunctival autograft (LCAU) in pterygium surgery."	9.17	Ten-year results of a randomized controlled trial comparing 0.02% mitomycin C and limbal conjunctival autograft in pterygium surgery. ( Cheng, LL; Ho, M; Jhanji, V; Young, AL, 2013)
"To determine the efficacy of preoperative subconjunctival injection of mitomycin C a day before surgery in the management of recurrent pterygium."	9.16	Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery. ( Khalifa, YM; Zaky, KS, 2012)
"To evaluate postoperative outcome and recurrence rate after primary pterygium excision using preoperative Mitomycin C (MMC) injection versus limbal conjunctival autograft transplantation (LCAT)."	9.15	Preoperative subpterygial mitomycin C injection versus limbal conjunctival autograft transplantation for prevention of pterygium recurrence. ( Farahat, HG; Mandour, SS; Mohamed, HM, 2011)
"To evaluate and compare the recurrence rates and complications between 2 therapeutic methods for primary pterygium: subconjunctival injection of mitomycin C (MMC) 1 month before bare scleral excision and conjunctival rotational flap with intraoperative MMC use."	9.14	Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications. ( Daneshvar, R; Ghate, MF; Ghooshkhanehi, H; Khakshoor, H; Razavi, ME; Shakeri, MT, 2010)
"In this prospective, randomized clinical study the authors sought to evaluate the effects of locally applied mitomycin C on peridural fibrosis during lumbar microdiscectomy."	9.13	Mitomycin protection of peridural fibrosis in lumbar disc surgery. ( Altan, T; Celik, S; Celik, SE; Göksu, K; Ince, I; Kapran, Z, 2008)
"To compare the efficacy and complications of conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT) vsintraoperative mitomycin C (MMC) and AMT for treatment of recurrent pterygium."	9.13	Transplantation of conjunctival limbal autograft and amniotic membrane vs mitomycin C and amniotic membrane in treatment of recurrent pterygium. ( Amozadeh, J; Fakhraee, G; Fallah, MR; Golabdar, MR; Moghimi, S; Zare, MA, 2008)
"The aim of this study was to evaluate the efficacy of mitomycin C in reducing postoperative adhesions following strabismus surgery."	9.11	Evaluation of mitomycin C in reducing postoperative adhesions in strabismus surgery. ( Chen, PL; Chen, WY; Lu, DW, 2005)
"To determine if a pterygium surgical procedure consisting of minimal conjunctival removal, excision of the hypertrophic subconjunctival fibrovascular tissue, application of mitomycin 0."	9.11	Pterygium surgery with mitomycin and tarsorrhaphy. ( Hamilton, DL; Williams, BL; Williams, EE; Wood, TO, 2005)
"To evaluate subconjunctival mitomycin C (MMC) injection efficacy and safety in patients with failing glaucoma non-penetrating filtering blebs."	9.10	Postoperative subconjunctival mitomycin-C injection after non-penetrating glaucoma surgery. ( Iester, M; Mermoud, A; Ravinet, E, 2002)
"To compare the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C."	9.10	A comparison of the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C in bilateral open-angle glaucoma. ( Kobayashi, H; Kobayashi, K; Okinami, S, 2003)
"To verify if partial intraoperative Tenon's capsule resection (PTCR) with adjunctive mitomycin C is effective in developing thin, avascular blebs in eyes undergoing Ahmed glaucoma valve insertion, and to assess the efficacy and safety of this procedure."	9.10	Partial Tenon's capsule resection with adjunctive mitomycin C in Ahmed glaucoma valve implant surgery. ( Susanna, R, 2003)
"Limbal conjunctival autograft transplantation or low-dose intraoperative mitomycin C application with conjunctival flap technique was performed on recurrent pterygium cases."	9.09	A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. ( Mutlu, FM; Sobaci, G; Tatar, T; Yildirim, E, 1999)
" 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin."	9.09	Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001)
"The use of adjunctive intraoperative mitomycin C has considerably improved the success rate of glaucoma filtering surgery."	9.08	The effect of reducing the exposure time of mitomycin C in glaucoma filtering surgery. ( Mégevand, GS; Murray, AD; Salmon, JF; Scholtz, RP, 1995)
"Twenty-eight eyes of 28 patients with advanced primary open-angle glaucoma undergoing primary trabeculectomy were randomized to either mitomycin C (0."	9.08	Low-dose mitomycin C trabeculectomy in patients with advanced glaucoma. ( Comegno, PE; Costa, VP; José, NK; Malta, RF; Vasconcelos, JP, 1996)
"Conjunctival autograft transplantation and postoperative mitomycin therapy are two adjuvant treatment methods shown to lessen the high pterygium recurrence rate seen with simple excision alone."	9.08	Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. ( Diaz, MD; Kloess, PM; Manning, CA; Yee, RW, 1997)
"04% mitomycin-C, either postoperatively for 2 weeks or intraoperatively as a single dose, as an adjunct in the surgical treatment of primary pterygium was evaluated."	9.08	Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium. ( Calişkan, S; Irkeç, M; Orhan, M, 1996)
"To evaluate the adjunctive use of mitomycin-C (MMC) during trabeculotomy and trabeculectomy for eyes with high-risk congenital glaucoma."	9.08	Mitomycin-C in congenital glaucoma. ( Agarwal, HC; Honavar, SG; Sanga, L; Sihota, R; Sood, NN, 1997)
"The purpose of the study was to examine the efficacy of intraoperative mitomycin C (MMC) in preventing recurrence of pterygium after excision and the postoperative complications encountered."	9.08	Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. ( Chew, S; Fan, DS; Kwok, PS; Lam, DS; Tso, MO; Wong, AK, 1998)
"The authors attempted to determine the effect of mitomycin-C (MMC) on postoperative corneal astigmatism in patients who underwent trabeculectomy or a triple procedure (trabeculectomy, extracapsular cataract extraction, and intraocular lens implantation)."	9.08	The effect of mitomycin-C on postoperative corneal astigmatism in trabeculectomy and a triple procedure. ( Choe, CM; Chung, HS; Hong, YJ; Kim, HK; Lee, YG, 1998)
"The effectiveness of intraoperative administration of mitomycin C and the occurrence of postoperative complications have been evaluated in 30 white patients with one recurrence of pterygium."	9.07	Effectiveness of intraoperative mitomycin C in the treatment of recurrent pterygium. ( Carpineto, P; Ciancaglini, M; Gallenga, PE; Lobefalo, L; Mastropasqua, L, 1994)
"We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery."	9.07	Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report. ( Frucht-Pery, J; Hemo, I; Ilsar, M, 1994)
"The administration of high doses of topical mitomycin C after pterygium excision causes a variety of complications."	9.07	The use of low-dose mitomycin C for prevention of recurrent pterygium. ( Frucht-Pery, J; Ilsar, M, 1994)
"This review details the current understanding of the mechanism of action and corneal effects of mitomycin C (MMC) for prophylactic prevention of stromal fibrosis after photorefractive keratectomy (PRK), and includes discussion of available information on dosage and exposure time recommended for MMC during PRK."	9.05	Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK. ( Carlos de Oliveira, R; Wilson, SE, 2020)
"To describe a patient with scleral dellen after pterygium excision with intraoperative mitomycin C."	8.81	Acute scleral thinning after pterygium excision with intraoperative mitomycin C: a case report of scleral dellen after bare sclera technique and review of the literature. ( Lin, JM; Shy, JD; Tsai, YY, 2002)
"To evaluate the clinical outcome of eyes which underwent primary trabeculectomy with adjunctive mitomycin C (MMC) for primary glaucoma."	8.79	Mitomycin C primary trabeculectomy in primary glaucoma of white patients. ( Nuijts, RM; Vernimmen, RC; Webers, CA, 1997)
"We performed retrospective analysis of 31 eyes with myopia that underwent canaloplasty modified with mitomycin C in a consecutive single-surgeon case series."	8.12	Is canaloplasty with mitomycin c a safe procedure in myopic glaucoma? ( Dietlein, TS; Dooling, V; Lappas, A, 2022)
"To examine the efficacy and safety of current trabeculectomy with mitomycin C in Japan for glaucomatous eyes with low intraocular pressure (IOP)."	7.96	Effectiveness of trabeculectomy with mitomycin C for glaucomatous eyes with low intraocular pressure on treatment eye drops. ( Higashide, T; Hirooka, K; Kiuchi, Y; Ohkubo, S; Sugimoto, Y; Sugiyama, K; Yuasa, Y, 2020)
"The aim of this study is to describe the effectiveness of trabeculectomy with mitomycin C and releasable suture in Posner-Schlossman syndrome (PSS) with secondary glaucoma."	7.91	The effectiveness of trabeculectomy with mitomycin C and releasable suture in posner-schlossman syndrome with secondary glaucoma: A case series. ( Artini, W; Bani, AP, 2019)
"To evaluate the safety and efficacy of mitomycin C (MMC) in haze formation after ultraviolet A/riboflavin corneal crosslinking (CXL) for progressive keratoconus."	7.88	Clinical Study of Mitomycin C in Reducing Haze Formation After Ultraviolet A/Riboflavin Crosslinking for Keratoconus. ( Li, Z; Mu, G; Pu, W; Tao, X; Xie, Y; Xu, H; Xu, L; Xu, Y; Zhu, W, 2018)
"To examine clinical outcomes following an initial trabeculectomy with mitomycin-C for secondary glaucoma associated with uveitis in Behçet disease (BD) patients."	7.85	Initial Trabeculectomy With Mitomycin-C for Secondary Glaucoma-associated With Uveitis in Behçet Disease Patients. ( Aihara, M; Fujino, Y; Kaburaki, T; Komae, K; Matsuda, J; Nakahara, H; Ohtomo, K; Okinaga, K; Takamoto, M; Tanaka, R, 2017)
"To examine the effect of mitomycin c and 5-flurouracil on treatment outcomes following Ahmed glaucoma valve implantation."	7.85	Effect of mitomycin c and 5-flurouracil adjuvant therapy on the outcomes of Ahmed glaucoma valve implantation. ( Cui, QN; Han, Y; Hsia, YC; Lin, SC; Mehta, N; Naseri, A; Porco, TC; Rose-Nussbaumer, J; Stamper, RL, 2017)
"To evaluate the intermediate and long-term outcomes of mitomycin C-enhanced trabeculectomy as a first glaucoma procedure in uveitic glaucoma."	7.85	Intermediate and Long-term Outcomes of Mitomycin C-enhanced Trabeculectomy as a First Glaucoma Procedure in Uveitic Glaucoma. ( Alharbi, AH; Aljadaan, I; Almobarak, FA; Morales, J, 2017)
"To evaluate the outcomes of trabeculectomy with mitomycin-C (MMC) in uveitis associated with Vogt-Koyanagi-Harada disease (VKH)."	7.83	Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease. ( Alharbi, AH; Aljadaan, I; Almobarak, FA; Morales, J, 2016)
"The present study aimed to investigate the efficacy of mitomycin-C (MMC) and infliximab (INF) in reducing adhesion and fibrosis following strabismus surgery."	7.83	Efficacy of mitomycin-C and infliximab in reducing adhesionand fibrosis following strabismus surgery. ( Çoşkun Yılmaz, B; Dinç, E; Güçlü, ES; Özcan Metin, T; Sarı, AA; Taşdelen, B, 2016)
"Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)."	7.80	The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014)
"The aim of the present study was to evaluate the efficacy and short-term safety of topical mitomycin-C, an antifibrotic agent, in preventing the recurrence of anastomotic strictures after surgical repair of esophageal atresia (EA)."	7.80	Topical mitomycin-C application in recurrent esophageal strictures after surgical repair of esophageal atresia. ( Chapuy, L; Faure, C; Pomerleau, M, 2014)
"To evaluate the surgical outcome of Ahmed glaucoma valve (AGV) implantation with a new technique of mitomycin C (MMC) application."	7.80	Use of Mitomycin C to reduce the incidence of encapsulated cysts following ahmed glaucoma valve implantation in refractory glaucoma patients: a new technique. ( Huang, W; Wang, W; Zhang, X; Zhou, M, 2014)
"Mitomycin C (MMC), as it could reduce tissue adhesions and scar formation, has been widely adopted in pterygium surgery to lower the recurrence rate."	7.79	[Mitomycin C related complications shouldn't be neglected in the pterygium surgery]. ( Shi, WY; Wang, FH, 2013)
"To report outcomes of deep sclerectomy (DS) with intraoperative mitomycin C (MMC) application in eyes with previous failed glaucoma surgery (GS) and/or cataract extraction (CE)."	7.78	Deep sclerectomy with mitomycin C in eyes with failed glaucoma surgery and pseudophakia. ( Anand, N; Wechsler, D, 2012)
"The purposes of this study were to investigate the effects of topically administrated Tacrolimus and Octreotide on modulation of postoperative scarring in experimental glaucoma filtration surgery and to compare the antifibrotic properties of these agents with mitomycin-C (MMC)."	7.78	Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery. ( Arslan, S; Aydemir, O; Dağlı, AF; Güler, M, 2012)
"To investigate the efficacy and safety of mitomycin C (MMC)-augmented deep sclerectomy with implant (DSCI) in primary open-angle glaucoma (POAG) and exfoliation glaucoma (ExG) patients."	7.77	Mitomycin C-augmented deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma: a three-year prospective study. ( Ollikainen, ML; Puustjärvi, TJ; Rekonen, PK; Teräsvirta, ME; Uusitalo, HM, 2011)
"To investigate whether topical administration of pirfenidone eye drops could be used to prevent postoperative scarring in a rabbit model of experimental glaucoma filtration surgery."	7.77	Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. ( Lin, X; Sun, G; Wu, K; Yu, M; Zhong, H, 2011)
"To report the long-term complications and rate of local recurrence in a cohort of patients with histopathologically confirmed conjunctival melanoma (CM) treated with adjuvant topical mitomycin C (MMC)."	7.77	Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. ( Ditta, LC; Shildkrot, Y; Wilson, MW, 2011)
"To evaluate the safety and efficacy of using fibrin glue in cases of recurrent pterygium treated with pterygium excision and conjunctival autograft combined with mitomycin C."	7.77	Management of recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin glue. ( Boimer, C; Lee, K; Shehadeh-Mashor, R; Slomovic, AR; Srinivasan, S; Tomkins, O, 2011)
"To investigate the efficacy and safety of mitomycin C (MMC)-augmented deep sclerectomy with implant (DSCI) in patients with primary open-angle glaucoma (POAG) and exfoliation glaucoma (ExG)."	7.76	Mitomycin-C-augmented deep sclerectomy in patients with primary open-angle glaucoma and exfoliation glaucoma: a 1-year prospective study. ( Ollikainen, M; Puustjärvi, T; Rekonen, P; Teräsvirta, M; Uusitalo, H, 2010)
"To determine the outcome and safety of nonlaser endonasal dacryocystorhinostomy (NLEN-DCR) with the use of adjunctive mitomycin C (MMC) in congenital, traumatic, and primary acquired nasolacrimal duct obstruction in adults."	7.76	Nonlaser endoscopic endonasal dacryocystorhinostomy with adjunctive mitomycin C in nasolacrimal duct obstruction in adults. ( Dolmetsch, AM, 2010)
"To evaluate the effectiveness of intra-operative Mitomycin-C application after pterygium surgery in Irrua, Nigeria."	7.76	Effectiveness of intra-operative Mitomycin-C in reducing the recurrence of pterygium in Irrua, Nigeria. ( Dawodu, OA; Eguaoje, IE; Enock, ME; Fuh, UC; Omoti, AE, 2010)
"To investigate the relationship between intrascleral bleb height and intraocular pressure (IOP) following deep sclerectomy with collagen implant (DSCI) and mitomycin C (MMC) in eyes with clinically flat blebs."	7.76	Postoperative IOP is related to intrascleral bleb height in eyes with clinically flat blebs following deep sclerectomy with collagen implant and mitomycin. ( Mavrakanas, N; Mendrinos, E; Shaarawy, T, 2010)
"02% mitomycin C (MMC) in the treatment of primary pterygium and to evaluate its safety and efficacy."	7.75	Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02% mitomycin C in primary pterygium excision. ( Cheng, LL; Lam, DS; Lam, PT; Leung, GY; Tam, PM; Young, AL, 2009)
"Two patients developed bleb-related ocular infection attributable to Gemella haemolysans and Gemella morbillorum after trabeculectomy with adjunctive mitomycin C."	7.75	Gemella species-associated late-onset endophthalmitis after trabeculectomy with adjunctive mitomycin C. ( Katada, T; Kawakami, H; Mikamo, H; Mochizuki, K; Sawada, A; Watanabe, K; Yamamoto, T, 2009)
"These results suggest that topical mitomycin is not effective for avoiding tracheal stenosis and may provoke the opposite effect if the dose is not carefully selected."	7.74	Effect of mitomycin in the surgical treatment of tracheal stenosis. ( González Bombardiere, S; Guilemany Toste, JM; Iñiguez-Cuadra, M; Iñiguez-Cuadra, R; Iñiguez-Sasso, R; Jofré Pavez, D; San Martín Prieto, J; Zúñiga Erranz, S, 2008)
"Topography-guided PRK with mitomycin C was safe and reasonably effective for the treatment of hyperopia after RK."	7.74	Customized topography-guided photorefractive keratectomy with the MEL-70 platform and mitomycin C to correct hyperopia after radial keratotomy. ( de Souza, DC; Ghanem, EA; Ghanem, RC; Ghanem, VC; Kara-José, N, 2008)
"To conduct a pilot study evaluating the efficacy and safety of limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C treatment for recurrent pterygium."	7.73	Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium. ( Amano, S; Hara, R; Miyai, T; Miyata, K; Nejima, R; Yonemura, T, 2005)
"To report a case of postoperative cystic epithelial downgrowth treated with needle aspiration and intralesional administration of mitomycin C."	7.73	Treatment of cystic epithelial downgrowth with intralesional administration of mitomycin C. ( Chiu, SI; Tse, RK; Yu, CS, 2005)
"To prospectively study the evolution of possible high risk features of conjunctival filtration blebs like avascularity, transconjunctival oozing (TCO), and leaks after mitomycin C (MMC) enhanced glaucoma surgery."	7.73	Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. ( Anand, N; Arora, S; Clowes, M, 2006)
"Antimetabolites, especially mitomycin C (MMC), increase the incidence of late bleb-related endophthalmitis in trabeculectomy."	7.73	Determinants of bleb morphology in minimally invasive, clear-cornea micropenetrating glaucoma surgery with mitomycin C. ( Flesner, P; Jensen, PK; Kessing, SV, 2006)
"To report a patient with dry eye after bilateral photorefractive keratectomy (PRK) with mitomycin C treatment in one eye."	7.73	Dry eye after photorefractive keratectomy with adjuvant mitomycin C. ( Diakonis, VF; Ginis, H; Kymionis, GD; Pallikaris, I; Tsiklis, NS, 2006)
"To report a case of scleral melting noted 16 years after pterygium excision with postoperative adjuvant topical Mitomycin C (MMC)."	7.73	Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. ( Azwa, JA; Ibrahim, M; Raihan, IS; Wan Norliza, WM, 2006)
"With adequate inflammation suppression, phacotrabeculectomy with mitomycin C is an effective and safe therapeutic option for the management of secondary cataract and glaucoma in uveitic eyes."	7.73	Phacotrabeculectomy with mitomycin C in patients with uveitis. ( Ahn, JK; Park, KH; Park, UC; Yu, HG, 2006)
"The aim of this study was to evaluate the effectiveness and safety of combining application of mitomycin and/or amnion transplantation when carrying out pterygium resection."	7.73	[Clinical study in combining application of mitomycin and amnion transplantation together with pterygium resection]. ( Huang, Y; Wang, B; Ye, Q, 2005)
"To assess the role of mitomycin C (MMC) in the management of pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction."	7.72	Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. ( Annino, DJ; Goguen, LA, 2003)
"Comparison of fornix- and limbus-based conjunctival flaps with respect to cystic bleb-related complications of trabeculectomy with high-dose mitomycin C (MMC) in pediatric and young adult glaucoma."	7.72	Cystic bleb formation and related complications in limbus- versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. ( Bunce, C; Cordeiro, MF; Khaw, PT; Wells, AP, 2003)
"To investigate the influence of 5-fluorouracil (5-FU) and mitomycin C (MMC) on the postoperative adhesions following strabismus surgery in rabbits."	7.72	Effects of intraoperative sponge mitomycin C and 5-fluorouracil on scar formation following strabismus surgery in rabbits. ( Düzcan, E; Eşme, A; Ozden, S; Tatlipinar, S; Yaylali, V; Yildirim, C, 2004)
"To evaluate long term complications after pterygium excision with mitomycin C (MMC) application."	7.72	Mitomycin C for pterygium: long term evaluation. ( Frucht-Pery, J; Ilsar, M; Landau, D; Raiskup, F; Solomon, A, 2004)
"To describe the surgical technique and clinical outcomes of a procedure for refractory glaucoma, concurrent Baerveldt glaucoma implant (BGI) and trabeculectomy with mitomycin C."	7.71	Combined Baerveldt glaucoma drainage implant and trabeculectomy with mitomycin C for refractory glaucoma. ( Budenz, DL; Bueche, M; Feuer, W; Nguyen, QH; Nicolela, MT; Palmberg, PF; Scott, IU; Singh, K, 2002)
"Retrospective review of consecutive cases of pediatric glaucoma that underwent mitomycin C augmented trabeculectomy between January 1991 and December 1995."	7.70	Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. ( Beck, AD; Lynch, MG; Lynn, MJ; Noe, R; Wilson, WR, 1998)
"To evaluate the surgical results and complications of mitomycin C-augmented trabeculectomy in refractory developmental glaucoma."	7.70	Surgical results and complications of mitomycin C-augmented trabeculectomy in refractory developmental glaucoma. ( Mandal, AK; Naduvilath, TJ; Prasad, K, 1999)
"To evaluate the effectiveness and safety of trabeculectomy with mitomycin-C (MMC) in the management of childhood glaucomas."	7.70	Trabeculectomy with mitomycin-C in the treatment of pediatric glaucomas. ( Belmonte, SJ; Liebmann, JM; Ritch, R; Sidoti, PA, 2000)
"To evaluate the efficiency of mitomycin C (MMC) in limiting the postoperative inflammatory response and scarring after strabismus surgery."	7.70	Histologic effect of mitomycin C on strabismus surgery in the rabbit. ( Akaishi, PM; De Luca, IM; Minguini, N; Monteiro de Carvalho, KM, 2000)
"Twenty-one eyes of 21 patients with refractory glaucoma underwent glaucoma surgery involving placement of a modified Molteno implant and intraoperative application of mitomycin C."	7.69	Mitomycin C as adjunctive therapy with glaucoma implant surgery. ( Nicolela, MT; Susanna, R; Takahashi, WY, 1994)
"Mitomycin C (MMC) was used as a perioperative adjunct during trabeculectomy for 51 consecutive cases of complicated glaucoma."	7.69	Mitomycin C for trabeculectomy in complicated glaucoma: preliminary results after 6 months. ( Krieglstein, GK; Mietz, H, 1994)
"To determine whether filtering blebs resulting from adjunctive use of mitomycin C (MMC) leads to an increased risk of endophthalmitis."	7.69	Bleb-related endophthalmitis after trabeculectomy with mitomycin C. ( Bergstrom, TJ; Higginbotham, EJ; Karp, KO; Lichter, PR; Musch, DC; Skuta, GL; Stevens, RK, 1996)
"The purposes of this study are to examine the complications and results of a novel approach to the use of mitomycin-C in pterygium surgery; to identify the lowest effective dosage required to prevent recurrence; and to select those high-risk pterygia that could benefit from mitomycin-C use."	7.69	Indications for and complications of mitomycin-C in pterygium surgery. ( Anduze, AL; Burnett, JM, 1996)
"To evaluate acute retinal vein occlusion as a potential complication of trabeculectomy with mitomycin C in cases of advanced glaucoma."	7.69	Retinal vein occlusion after trabeculectomy with mitomycin C. ( Dev, S; Herndon, L; Shields, MB, 1996)
"Combined penetrating keratoplasty and trabeculectomy with mitomycin-C should be considered for selected patients with uncontrolled glaucoma and corneal disease who have sufficient conjunctiva for a filtering procedure."	7.69	Management of coexisting corneal disease and glaucoma by combined penetrating keratoplasty and trabeculectomy with mitomycin-C. ( Araujo, SV; Cohen, EJ; Figueiredo, RS; Katz, LJ; Rapuano, CJ; Wilson, RP, 1996)
"The authors studied the efficacy and complications of intraoperative mitomycin-C in glaucoma associated with ocular inflammation."	7.69	Intraoperative mitomycin-C for glaucoma associated with ocular inflammation. ( McGehee, RF; Pederson, JE; Wright, MM, 1997)
"The purpose of the study is to determine the safety and efficacy of mitomycin C-augmented trabeculectomy in children with developmental glaucoma treated previously by conventional procedures."	7.69	Mitomycin C-augmented trabeculectomy in refractory congenital glaucoma. ( Jayagandan, A; John, T; Mandal, AK; Walton, DS, 1997)
"To evaluate the safety and efficacy of trabeculectomy with mitomycin-C in the management of postkeratoplasty glaucoma."	7.69	Trabeculectomy with mitomycin-C for postkeratoplasty glaucoma: a preliminary study. ( Gupta, A; Kumar, S; Ram, J; Sharma, A, 1997)
"To determine whether 5-fluorouracil is effective in reducing scarring after strabismus surgery we used rectus muscle surgery in experimental animals to compare a single intraoperative dose of 5-fluorouracil with mitomycin C and to compare results in similarly treated controls not receiving these antimetabolites."	7.69	Intraoperative sponge 5-fluorouracil to reduce postoperative scarring in strabismus surgery. ( Evan, AP; Helveston, EM; Mora, JS; Sprunger, DT, 1997)
" Thirty-three months before, the patient had a pterygium excised and mitomycin C, 0."	7.68	Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. ( Fujitani, A; Hayasaka, S; Noda, S; Shibuya, Y, 1993)
"The use of topical mitomycin (mitomycin-C) as a medical adjunct to pterygium and glaucoma surgery is increasing."	7.68	Serious complications of topical mitomycin-C after pterygium surgery. ( Foster, CS; Martin, NF; Pfister, RR; Rubinfeld, RS; Speaker, MG; Stein, RM; Stoleru, S; Talley, AR, 1992)
"Right corneal melting and scleral necrosis developed in a 77-year-old man 5 months after pterygium excision followed by topical administration of mitomycin C drops (0."	7.68	Corneal melting after pterygium removal followed by topical mitomycin C therapy. ( Climenhaga, DB; Ewing-Chow, DA; Gilmour, GR; Romanchuk, KG; Underhill, JH, 1992)
"We found more pterygium recurrences in the MMC group."	6.78	[Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study]. ( Bouguila, H; Boujemaa, C; Chebbi, A; Lajili, Z; Malek, I; Nacef, L; Saida Ayed, S; Zghal, I, 2013)
"To study the clinical effect of trabeculectomy combined with Mitomycin C and removed suture."	6.71	[Trabeculectomy combined with mitomycin C and removed suture in glaucoma]. ( Feng, Y, 2003)
"Patients were followed for recurrence (defined as fibrovascular tissue invading the cornea >1."	6.71	A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium. ( Cheng, LL; Lam, DS; Leung, GY; Wong, AK; Young, AL, 2004)
" Combining the use of MMC with conjunctival autograft allows for decreased dosage and time of intraoperative exposure of mitomycin, thereby making it safer for application."	6.69	Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians. ( Law, FC; Wong, VA, 1999)
"To determine the rate of recurrence and complications after bare sclera excision of primary pterygia followed by low-dose mitomycin C (0."	6.68	A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. ( Ariyasu, RG; Chen, PP; Kaza, V; LaBree, LD; McDonnell, PJ, 1995)
"Late postoperative complications are similar with the exception of an increased incidence of Tenon cyst formation in the MMC-treated eyes."	6.68	Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. ( Bergstrom, TJ; Higginbotham, EJ; Johnson, AT; Katz, GJ; Lichter, PR; Musch, DC; Skuta, GL, 1995)
"This study is the largest series reported showing that topical application of MC is an efficient and safe treatment for recurrent esophageal stenosis in children."	5.51	Efficacy and Safety of the Local Application of Mitomycin C to Recurrent Esophageal Strictures in Children. ( Bridenne, M; Fayoux, P; Gottrand, F; Hauser, B; Lachaux, A; Lemale, J; Ley, D; Michaud, L; Rebouissoux, L; Viala, J, 2019)
"Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)."	5.48	Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018)
"Mitomycin was applied in 15 patients."	5.40	Early endoscopic dilation and mitomycin application in the treatment of acquired tracheal stenosis. ( Castro, L; De la Serna, O; De La Torre, C; Dominguez, E; Encinas, JL; Hernandez, F; Lopez-Fernandez, S; Menendez, JJ; Ortiz, R; Santamaria, ML; Tovar, JA; Vazquez, J, 2014)
"Mitomycin C (MMC) is a widely used agent for the adjuvant treatment of bladder tumors."	5.35	Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! ( Cek, M; Fazlioglu, A; Kurtulus, FO; Parlakkilic, O; Tandogdu, Z, 2009)
" However, for moderate myopia and shallow depth, low dosing appears to be equally effective."	5.35	Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. ( Krueger, RR; Thornton, I; Xu, M, 2008)
"Epidural fibrosis was evaluated histologically."	5.32	Mitomycin C in preventing spinal epidural fibrosis in a laminectomy model in rats. ( Ebel, H; Ernestus, RI; Klug, N; Lee, JY; Stenzel, W; Wedekind, C, 2004)
"Astigmatism was reduced."	5.30	Single application mitomycin C in primary pterygium surgery. ( Pommerencke, C, 1998)
"Mitomycin C is a promising substance which improves substantially the prognosis of complicated cases of glaucoma."	5.29	[Initial experience with the use of mitomycin C in anti-glaucoma filtering surgery]. ( Liehneová, I; Rozsíval, P, 1994)
"No recurrence was noted within the 1st year in the primary pterygium group, whereas recurrence was observed in 3/24 eyes that had been treated for recurrent pterygium, equivalent to a recurrence rate of 12."	5.28	Pterygium excision using 193-nm excimer laser smoothing and topical mitomycin C. ( Schnelle, B; Seiler, T; Wollensak, J, 1992)
"The rates of recurrence (5% to 9%) and complications in eyes that had undergone excision and mitomycin C instillation were less than those in eyes that had had excision only."	5.28	Postoperative instillation of mitomycin C in the treatment of recurrent pterygium. ( Hayasaka, S; Noda, S; Setogawa, T; Yamamoto, Y, 1989)
"While trabeculectomy with mitomycin C has previously been the gold standard in penetrating glaucoma surgery, glaucoma drainage implants used early within glaucoma surgery were examined in the course of the tube versus trabeculectomy (TVT) study."	5.27	[Glaucoma Drainage Devices: Tube versus Trabeculectomy Study]. ( Alnawaiseh, M; Bula, AM; Rosentreter, A; Strzalkowski, P, 2018)
"This was a prospective, controlled, cohort study that included 64 eyes of 46 children younger than 12 years with uncontrolled glaucoma, who underwent trabeculectomy with mitomycin C in an institutional setting."	5.22	Excision of Tenon Capsule in Pediatric Trabeculectomy: A Controlled Study. ( Awadein, A; El Sayed, YM, 2016)
"To determine whether adjunctive mitomycin C (MMC) or amniotic membrane transplantation (AMT) improve the outcomes of Ahmed glaucoma valve (AGV) implantation."	5.22	Adjunctive Mitomycin C or Amniotic Membrane Transplantation for Ahmed Glaucoma Valve Implantation: A Randomized Clinical Trial. ( Doozandeh, A; Ghahari, E; Mahboobipour, H; Pakravan, M; Yazdani, S, 2016)
"The authors conducted a study to evaluate the effects and the safety of locally applied mitomycin C (MMC) on epidural fibrosis after microendoscopic discectomy (MED)."	5.17	Inhibition of epidural fibrosis after microendoscopic discectomy with topical application of mitomycin C: a randomized, controlled, double-blind trial. ( Cao, X; Hong, X; Liu, L; Sui, T; Wu, X, 2013)
"To compare the long-term outcome of pterygium surgery and the long-term effect on endothelial counts after mitomycin C (MMC) or limbal conjunctival autograft (LCAU) in pterygium surgery."	5.17	Ten-year results of a randomized controlled trial comparing 0.02% mitomycin C and limbal conjunctival autograft in pterygium surgery. ( Cheng, LL; Ho, M; Jhanji, V; Young, AL, 2013)
"This prospective study included 54 eyes with primary nasal pterygia that underwent pterygium surgery with a bare-sclera technique and intraoperative mitomycin C application."	5.17	Effects of intraoperative steroid injection on the outcome of pterygium surgery. ( Behrouz, MJ; Ghassemi, H; Kheirkhah, A; Nazari, R; Raju, VK; Safi, H, 2013)
"Tube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC 0."	5.16	Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. ( Brandt, JD; Budenz, DL; Feuer, WJ; Gedde, SJ; Herndon, LW; Schiffman, JC, 2012)
"To determine the efficacy of preoperative subconjunctival injection of mitomycin C a day before surgery in the management of recurrent pterygium."	5.16	Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery. ( Khalifa, YM; Zaky, KS, 2012)
"To evaluate postoperative outcome and recurrence rate after primary pterygium excision using preoperative Mitomycin C (MMC) injection versus limbal conjunctival autograft transplantation (LCAT)."	5.15	Preoperative subpterygial mitomycin C injection versus limbal conjunctival autograft transplantation for prevention of pterygium recurrence. ( Farahat, HG; Mandour, SS; Mohamed, HM, 2011)
"Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract."	5.14	Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. ( Chan, JC; Chiu, TY; Kwong, YY; Lai, JS; Lam, DS; Lam, SW; Leung, DY; Li, FC; Tham, CC, 2009)
"A 350-mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC 0."	5.14	Three-year follow-up of the tube versus trabeculectomy study. ( Brandt, JD; Budenz, DL; Feuer, WJ; Gedde, SJ; Herndon, LW; Schiffman, JC, 2009)
"Between July 2005 and October 2007, 61 consecutive medically uncontrolled glaucoma patients scheduled for first-time trabeculectomy were randomized to 1 of 3 study topical medication groups: nonsteroidal anti-inflammatory drugs (ketorolac), steroids (fluorometholone), or placebo (artificial tears)."	5.14	Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. ( Breusegem, C; Fieuws, S; Renier, C; Spielberg, L; Stalmans, I; Van de Veire, S; Van Ginderdeuren, R; Vandewalle, E; Zeyen, T, 2010)
"To evaluate and compare the recurrence rates and complications between 2 therapeutic methods for primary pterygium: subconjunctival injection of mitomycin C (MMC) 1 month before bare scleral excision and conjunctival rotational flap with intraoperative MMC use."	5.14	Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications. ( Daneshvar, R; Ghate, MF; Ghooshkhanehi, H; Khakshoor, H; Razavi, ME; Shakeri, MT, 2010)
"Combined phacotrabeculectomy with adjunctive mitomycin C may be marginally more effective than phacoemulsification alone in controlling IOP in medically controlled CACG eyes with coexisting cataract."	5.13	Phacoemulsification versus combined phacotrabeculectomy in medically controlled chronic angle closure glaucoma with cataract. ( Chan, CH; Chan, JC; Chi, CC; Chiu, TY; Kwong, YY; Lai, JS; Lam, DS; Lam, SW; Leung, DY; Li, FC; Poon, AS; Tham, CC; Yick, DW, 2008)
"In this prospective, randomized clinical study the authors sought to evaluate the effects of locally applied mitomycin C on peridural fibrosis during lumbar microdiscectomy."	5.13	Mitomycin protection of peridural fibrosis in lumbar disc surgery. ( Altan, T; Celik, S; Celik, SE; Göksu, K; Ince, I; Kapran, Z, 2008)
"To compare the efficacy and complications of conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT) vsintraoperative mitomycin C (MMC) and AMT for treatment of recurrent pterygium."	5.13	Transplantation of conjunctival limbal autograft and amniotic membrane vs mitomycin C and amniotic membrane in treatment of recurrent pterygium. ( Amozadeh, J; Fakhraee, G; Fallah, MR; Golabdar, MR; Moghimi, S; Zare, MA, 2008)
"The purpose of our study was to assess intraocular pressure control (IOP) and postoperative complications in nonpenetrating very deep sclerectomy (NPVDS) with reticulated hyaluronic acid implant (SKGEL) and Mitomycin C (MMC)."	5.13	Nonpenetrating very deep sclerectomy with reticulated hyaluronic acid implant in glaucoma treatment. ( Forminśka-Kapuścik, M; Gierek-Ciaciura, S; Leszczyński, R; Mrukwa-Kominek, E; Rokita-Wala, I, 2008)
"To compare the long-term effects of low-dosage mitomycin C (MMC) in both deep sclerectomy (DSMMC) and trabeculectomy (TPMMC) on intraocular pressure (IOP)."	5.13	Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up. ( Casuccio, A; Cillino, G; Cillino, S; Di Pace, F; Lodato, G, 2008)
" Bleeding, infection, and fever were most common with adjuvant treatment (BCG or mitomycin)."	5.12	Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma. ( Linehan, J; Schoenberg, M; Seltzer, E; Smith, AB; Thacker, K, 2021)
"To evaluate the anti-haze effect and visual outcome after intraoperative mitomycin C (MMC) use during photorefractive keratectomy (PRK) in myopia or myopic astigmatism patients."	5.12	Mitomycin C for the prevention of corneal haze in photorefractive keratectomy: a meta-analysis and trial sequential analysis. ( Chang, YM; Chien, KH; Lee, CH; Liang, CM; Weng, TH, 2021)
"The aim of this study was to evaluate the efficacy of mitomycin C in reducing postoperative adhesions following strabismus surgery."	5.11	Evaluation of mitomycin C in reducing postoperative adhesions in strabismus surgery. ( Chen, PL; Chen, WY; Lu, DW, 2005)
"To determine if a pterygium surgical procedure consisting of minimal conjunctival removal, excision of the hypertrophic subconjunctival fibrovascular tissue, application of mitomycin 0."	5.11	Pterygium surgery with mitomycin and tarsorrhaphy. ( Hamilton, DL; Williams, BL; Williams, EE; Wood, TO, 2005)
"To evaluate subconjunctival mitomycin C (MMC) injection efficacy and safety in patients with failing glaucoma non-penetrating filtering blebs."	5.10	Postoperative subconjunctival mitomycin-C injection after non-penetrating glaucoma surgery. ( Iester, M; Mermoud, A; Ravinet, E, 2002)
"To evaluate the results of the prophylactic use of mitomycin-C to inhibit haze formation after excimer laser photorefractive keratectomy (PRK) for medium and high myopia in eyes that were not good candidates for laser in situ keratomileusis (LASIK)."	5.10	Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. ( Carones, F; Scandola, E; Vacchini, L; Vigo, L, 2002)
"To compare the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C."	5.10	A comparison of the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C in bilateral open-angle glaucoma. ( Kobayashi, H; Kobayashi, K; Okinami, S, 2003)
"To verify if partial intraoperative Tenon's capsule resection (PTCR) with adjunctive mitomycin C is effective in developing thin, avascular blebs in eyes undergoing Ahmed glaucoma valve insertion, and to assess the efficacy and safety of this procedure."	5.10	Partial Tenon's capsule resection with adjunctive mitomycin C in Ahmed glaucoma valve implant surgery. ( Susanna, R, 2003)
"To compare the efficacy and safety of subconjunctival and intrascleral applications of mitomycin C (MMC) in trabeculectomy for high-risk glaucomas."	5.09	Assessing the role of subconjunctival versus intrascleral application of mitomycin C in high-risk trabeculectomies. ( Agarwal, HC; Saigal, D; Sihota, R, 2001)
"Limbal conjunctival autograft transplantation or low-dose intraoperative mitomycin C application with conjunctival flap technique was performed on recurrent pterygium cases."	5.09	A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. ( Mutlu, FM; Sobaci, G; Tatar, T; Yildirim, E, 1999)
"To evaluate the efficacy and safety of application of mitomycin-C (MMC) in combined and separate trabeculectomy and penetrating keratoplasty for the treatment of coexisting corneal disease and glaucoma."	5.09	Mitomycin-C in combined or two-stage procedure trabeculectomy followed by penetrating keratoplasty. ( Chowers, I; Ticho, U, 1999)
"To evaluate the effect of ab-interno goniotrabeculotomy (AIGT) on the intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG), compared with the effects of mitomycin C trabeculectomy (MT)."	5.09	Ab-interno goniotrabeculotomy versus mitomycin C trabeculectomy for adult open-angle glaucoma: a 2-year randomized clinical trial. ( Hitchings, RA; Quaranta, CA; Quaranta, L, 1999)
" 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin."	5.09	Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001)
"The use of adjunctive intraoperative mitomycin C has considerably improved the success rate of glaucoma filtering surgery."	5.08	The effect of reducing the exposure time of mitomycin C in glaucoma filtering surgery. ( Mégevand, GS; Murray, AD; Salmon, JF; Scholtz, RP, 1995)
"The authors assessed the efficacy of adjunctive intraoperative mitomycin C to produce lower intraocular pressures (IOPs) in patients with complicated glaucoma who underwent double-plate Molteno implantation."	5.08	Adjunctive mitomycin C in Molteno implant surgery. ( Cardakli, UF; Eisele, JR; Heatley, GA; Kaufman, PL; Perkins, TW, 1995)
"Twenty-eight eyes of 28 patients with advanced primary open-angle glaucoma undergoing primary trabeculectomy were randomized to either mitomycin C (0."	5.08	Low-dose mitomycin C trabeculectomy in patients with advanced glaucoma. ( Comegno, PE; Costa, VP; José, NK; Malta, RF; Vasconcelos, JP, 1996)
"The purpose of the study is to determine whether the intraoperative application of subconjunctival mitomycin C (MMC), during combined phacoemulsification and trabeculectomy, is an effective means of improving filtration, defined as overall lower intraocular pressure (IOP) and less antiglaucoma medication use."	5.08	A randomized study of mitomycin augmentation in combined phacoemulsification and trabeculectomy. ( Alward, WL; Barad, JP; Carlson, DW; Carney, BL; Zimmerman, MB, 1997)
"Conjunctival autograft transplantation and postoperative mitomycin therapy are two adjuvant treatment methods shown to lessen the high pterygium recurrence rate seen with simple excision alone."	5.08	Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. ( Diaz, MD; Kloess, PM; Manning, CA; Yee, RW, 1997)
"04% mitomycin-C, either postoperatively for 2 weeks or intraoperatively as a single dose, as an adjunct in the surgical treatment of primary pterygium was evaluated."	5.08	Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium. ( Calişkan, S; Irkeç, M; Orhan, M, 1996)
"To establish the long-term, dose-response relationship between the concentration of and duration of exposure to mitomycin to a decrease in intraocular pressure (IOP) and fewer complications."	5.08	A long-term dose-response study of mitomycin in glaucoma filtration surgery. ( Bhatnagar, R; Katz, JD; Krishnadas, R; Ramakrishnan, R; Robin, AL; Selvaraj, S; Skuta, GL; Smith, SD, 1997)
"To evaluate the adjunctive use of mitomycin-C (MMC) during trabeculotomy and trabeculectomy for eyes with high-risk congenital glaucoma."	5.08	Mitomycin-C in congenital glaucoma. ( Agarwal, HC; Honavar, SG; Sanga, L; Sihota, R; Sood, NN, 1997)
"The purpose of the study was to examine the efficacy of intraoperative mitomycin C (MMC) in preventing recurrence of pterygium after excision and the postoperative complications encountered."	5.08	Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. ( Chew, S; Fan, DS; Kwok, PS; Lam, DS; Tso, MO; Wong, AK, 1998)
"The authors attempted to determine the effect of mitomycin-C (MMC) on postoperative corneal astigmatism in patients who underwent trabeculectomy or a triple procedure (trabeculectomy, extracapsular cataract extraction, and intraocular lens implantation)."	5.08	The effect of mitomycin-C on postoperative corneal astigmatism in trabeculectomy and a triple procedure. ( Choe, CM; Chung, HS; Hong, YJ; Kim, HK; Lee, YG, 1998)
"In the diclofenac group (n = 14), the preoperative intraocular pressure of 30."	5.08	The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. ( Cate, EA; Dubiner, HB; Kent, AR; Mundorf, TK; Stewart, JA; Stewart, WC; Whitaker, R, 1998)
"Adjuvant intraperitoneal therapy of gastric cancer by mitomycin bound to activated carbon particles is associated with an increased rate of postoperative complications."	5.08	Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. ( Czeijka, M; Holzberger, P; Jatzko, G; Lisborg, P; Neudorfer, H; Potrc, S; Rabl, H; Repse, S; Rosen, HR; Sandbichler, P; Zacherl, J, 1998)
"The authors assess whether adjunctive mitomycin C improves Molteno tube shunt surgery in terms of intraocular pressure (IOP), visual acuity, and complication rates."	5.08	The effect of mitomycin C on Molteno implant surgery: a 1-year randomized, masked, prospective study. ( Bhavnani, V; Brizendine, E; Burgoyne, J; Cantor, L; Hoop, J; Sanders, S, 1998)
"To compare the intraocular pressure and hypotony outcomes of primary phakic trabeculectomies with no mitomycin C (MMC), shorter MMC, and longer MMC exposure."	5.08	Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C. ( Ginde, SA; Kim, C; Kim, YY; Kupin, TH; Lee, D; Ren, J; Sexton, RM; Shin, DH, 1998)
"The effectiveness of intraoperative administration of mitomycin C and the occurrence of postoperative complications have been evaluated in 30 white patients with one recurrence of pterygium."	5.07	Effectiveness of intraoperative mitomycin C in the treatment of recurrent pterygium. ( Carpineto, P; Ciancaglini, M; Gallenga, PE; Lobefalo, L; Mastropasqua, L, 1994)
"We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery."	5.07	Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report. ( Frucht-Pery, J; Hemo, I; Ilsar, M, 1994)
"The administration of high doses of topical mitomycin C after pterygium excision causes a variety of complications."	5.07	The use of low-dose mitomycin C for prevention of recurrent pterygium. ( Frucht-Pery, J; Ilsar, M, 1994)
"This review details the current understanding of the mechanism of action and corneal effects of mitomycin C (MMC) for prophylactic prevention of stromal fibrosis after photorefractive keratectomy (PRK), and includes discussion of available information on dosage and exposure time recommended for MMC during PRK."	5.05	Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK. ( Carlos de Oliveira, R; Wilson, SE, 2020)
"The Tube Versus Trabeculectomy (TVT) Study is a multicenter randomized clinical trial comparing the safety and efficacy of tube-shunt surgery to trabeculectomy with mitomycin (MMC) in eyes with previous cataract and/or unsuccessful glaucoma surgery."	4.86	Review of results from the Tube Versus Trabeculectomy Study. ( Gedde, SJ; Heuer, DK; Parrish, RK, 2010)
"To describe a patient with scleral dellen after pterygium excision with intraoperative mitomycin C."	4.81	Acute scleral thinning after pterygium excision with intraoperative mitomycin C: a case report of scleral dellen after bare sclera technique and review of the literature. ( Lin, JM; Shy, JD; Tsai, YY, 2002)
"To evaluate the clinical outcome of eyes which underwent primary trabeculectomy with adjunctive mitomycin C (MMC) for primary glaucoma."	4.79	Mitomycin C primary trabeculectomy in primary glaucoma of white patients. ( Nuijts, RM; Vernimmen, RC; Webers, CA, 1997)
"Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy."	4.40	Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023)
"This was a single-center, nonrandomized retrospective cohort study of 998 eyes from 854 patients with glaucoma who underwent trabeculectomy with mitomycin C."	4.31	Trabeculectomy Tenon Advancement Technique May Reduce Bleb-Related Infections. ( Higashide, T; Mambo, Y; Ohkubo, S; Okayama, M; Sugiyama, K; Tsuchiya, S; Udagawa, S; Wajima, R; Yamashita, Y, 2023)
" Mitomycin C has been used adjunctively in various procedures, including pterygium excision."	4.31	Inadvertent filtering bleb due to extracapsular cataract extraction wound reopening after mitomycin C use: a case report. ( Chaidaroon, W; Pathanapitoon, K; Upaphong, P, 2023)
"We performed retrospective analysis of 31 eyes with myopia that underwent canaloplasty modified with mitomycin C in a consecutive single-surgeon case series."	4.12	Is canaloplasty with mitomycin c a safe procedure in myopic glaucoma? ( Dietlein, TS; Dooling, V; Lappas, A, 2022)
"To determine the incidence of postoperative complications following combined trabeculotomy trabeculectomy with mitomycin C (CTTM) for congenital glaucoma (CG), in addition to documentation of some unusual complications and possible ways to manage these complications safely with minimal morbidity."	4.02	Common and rare complications following filtering surgery for children with congenital glaucoma; a5 years study. ( Sayed, KM, 2021)
"A prospective, noncomparative case series of 30 eyes of 30 Chinese patients with mixed types of glaucoma who underwent fornix-based trabeculectomy combined with intraoperative mitomycin C application."	3.96	The Tenons' Layer Reposition Approach of Trabeculectomy: A Longitudinal Case Series of a Mixed Group of Glaucoma Patients. ( Baig, N; Chan, PP; Chan, TCY; Lai, G; Wong, LYN, 2020)
"Adult patients who have undergone glaucoma surgery including a tube shunt, trabeculectomy with mitomycin C, trabectome, or transcleral cyclophotocoagulation from June 1, 2015 to August 30, 2017 at a single institution."	3.96	Reoperations for Complications Within 90 Days After Glaucoma Surgery. ( Al-Aswad, LA; Blumberg, DM; Chu, CK; Cioffi, GA; Liebmann, JM, 2020)
"PRéCIS:: Glaucoma drainage devices (GDD) by Australian and New Zealand glaucomatologists are implanted superotemporally under a peribulbar anesthesia without the use of mitomycin C."	3.96	Glaucoma Drainage Device Technique in a Cohort of Experienced Glaucoma Surgeons in Australia and New Zealand. ( Craig, JE; Danesh-Meyer, HV; Lee, GA; Liu, L, 2020)
"To examine the efficacy and safety of current trabeculectomy with mitomycin C in Japan for glaucomatous eyes with low intraocular pressure (IOP)."	3.96	Effectiveness of trabeculectomy with mitomycin C for glaucomatous eyes with low intraocular pressure on treatment eye drops. ( Higashide, T; Hirooka, K; Kiuchi, Y; Ohkubo, S; Sugimoto, Y; Sugiyama, K; Yuasa, Y, 2020)
"To report a new approach for the treatment of severe ocular hypotony secondary to glaucoma filtering surgery with mitomycin C by injecting autologous eye platelet-rich plasma (E-PRP) in the anterior chamber to block excessive diffuse filtration through an abnormally thinned sclera."	3.91	Treatment of chronic and extreme ocular hypotension following glaucoma surgery with intraocular platelet-rich plasma: A case report. ( Abdalrahman, O; Alio Del Barrio, JL; Alio, JL; Rodriguez, AE, 2019)
"The aim of this study is to describe the effectiveness of trabeculectomy with mitomycin C and releasable suture in Posner-Schlossman syndrome (PSS) with secondary glaucoma."	3.91	The effectiveness of trabeculectomy with mitomycin C and releasable suture in posner-schlossman syndrome with secondary glaucoma: A case series. ( Artini, W; Bani, AP, 2019)
"Rabbit model studies suggested better morphology blebs with equal intraocular pressure (IOP) efficacy as a standard mitomycin C (MMC) trabeculectomy using a novel slow-release drug delivery antifibrotic system delivering small quantities of MMC and 5-fluorouracil (5-FU)."	3.91	Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model. ( Ayyala, RS; Blake, D; Fullerton, M; Greenberg, E; John, V; Le, C; Mancera, N; Margo, C; Muddasani, N; Satija, C; Singh, S; Swann, FB; Wall, J; Zhang, Z; Zurakowski, D, 2019)
"Phacotrabeculectomy with adjunctive mitomycin C is a good option for the management of coexisting cataract and glaucoma."	3.91	Phacotrabeculectomy in Eyes With Uveitic Glaucoma: A Retrospective Case-Control Study. ( Balekudaru, S; Biswas, J; Ganesh, SK; George, AE; George, R; Lingam, V; Wadke, V, 2019)
"Wider area bleb revision using bleb knife with adjunctive mitomycin C (MMC) had a good success rate, according to strict success criteria, except in patients with neovascular glaucoma (NVG)."	3.91	Outcomes of Wider Area Bleb Revision Using Bleb Knife With Adjunctive Mitomycin C. ( Asaoka, R; Kiuchi, Y; Nakakura, S; Noguchi, A; Tabuchi, H; Tanabe, H, 2019)
"To evaluate the safety and efficacy of mitomycin C (MMC) in haze formation after ultraviolet A/riboflavin corneal crosslinking (CXL) for progressive keratoconus."	3.88	Clinical Study of Mitomycin C in Reducing Haze Formation After Ultraviolet A/Riboflavin Crosslinking for Keratoconus. ( Li, Z; Mu, G; Pu, W; Tao, X; Xie, Y; Xu, H; Xu, L; Xu, Y; Zhu, W, 2018)
"We report a case of a rare complication after trabeculotomy combined with a small trabeculectomy with mitomycin C in a young patient with juvenile glaucoma."	3.88	Urrets-Zavalia Syndrome After Combined Trabeculotomy-Trabeculectomy Surgery. ( Gericke, A; Hoffmann, EM; Klezlova, A; Liebezeit, S; Pfeiffer, N; Prokosch-Willing, V, 2018)
"The objective of this study is to investigate the results of an adaptive approach of bleb revision surgery for late onset hypotony after trabeculectomy with mitomycin C because of bleb leakage and/or scleral melting."	3.88	Results of an Adaptive Surgical Approach for Managing Late Onset Hypotony After Trabeculectomy With Mitomycin C. ( Hoffmann, EM; Lamparter, J; Pfeiffer, N; Prokosch-Willing, V; Toshev, AP; Ul Hassan, SN, 2018)
"To examine clinical outcomes following an initial trabeculectomy with mitomycin-C for secondary glaucoma associated with uveitis in Behçet disease (BD) patients."	3.85	Initial Trabeculectomy With Mitomycin-C for Secondary Glaucoma-associated With Uveitis in Behçet Disease Patients. ( Aihara, M; Fujino, Y; Kaburaki, T; Komae, K; Matsuda, J; Nakahara, H; Ohtomo, K; Okinaga, K; Takamoto, M; Tanaka, R, 2017)
"To examine the effect of mitomycin c and 5-flurouracil on treatment outcomes following Ahmed glaucoma valve implantation."	3.85	Effect of mitomycin c and 5-flurouracil adjuvant therapy on the outcomes of Ahmed glaucoma valve implantation. ( Cui, QN; Han, Y; Hsia, YC; Lin, SC; Mehta, N; Naseri, A; Porco, TC; Rose-Nussbaumer, J; Stamper, RL, 2017)
"To evaluate the intermediate and long-term outcomes of mitomycin C-enhanced trabeculectomy as a first glaucoma procedure in uveitic glaucoma."	3.85	Intermediate and Long-term Outcomes of Mitomycin C-enhanced Trabeculectomy as a First Glaucoma Procedure in Uveitic Glaucoma. ( Alharbi, AH; Aljadaan, I; Almobarak, FA; Morales, J, 2017)
"To evaluate the outcomes of trabeculectomy with mitomycin-C (MMC) in uveitis associated with Vogt-Koyanagi-Harada disease (VKH)."	3.83	Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease. ( Alharbi, AH; Aljadaan, I; Almobarak, FA; Morales, J, 2016)
"The present study aimed to investigate the efficacy of mitomycin-C (MMC) and infliximab (INF) in reducing adhesion and fibrosis following strabismus surgery."	3.83	Efficacy of mitomycin-C and infliximab in reducing adhesionand fibrosis following strabismus surgery. ( Çoşkun Yılmaz, B; Dinç, E; Güçlü, ES; Özcan Metin, T; Sarı, AA; Taşdelen, B, 2016)
"Consecutive prospective case series study to examine the 6-month outcome of 106 eyes [primary open-angle glaucoma (OAG), exfoliation glaucoma (XFG), and inflammatory glaucoma (ING)] that underwent TLE with mitomycin C performed by a single surgeon from September 2009 to September 2010 at Tokyo University Hospital."	3.81	Targeting a low-teen intraocular pressure by trabeculectomy with a fornix-based conjunctival flap: continuous Japanese case series by a single surgeon. ( Aihara, M; Aoyama, Y; Murata, H, 2015)
"To determine the occurrence of intraoperative and postoperative complications up to three years after primary phacotrabeculectomy with intraoperative use of Mitomycin C (MMC) in primary open angle (POAG) and primary angle closure glaucoma (PACG) patients, and the effect of postoperative complications on surgical outcome."	3.81	Complications and outcomes of primary phacotrabeculectomy with mitomycin C in a multi-ethnic asian population. ( Aquino, MC; Chen, DZ; Chew, P; Koh, V; Sng, C, 2015)
"To evaluate the long-term effectiveness and safety of mitomycin C (MMC)-augmented trabeculectomy undertaken within the first 2 years of life for the surgical management of glaucoma."	3.81	Long-Term Outcomes of Trabeculectomy Augmented with Mitomycin C Undertaken within the First 2 Years of Life. ( Bunce, C; Chiang, M; Jayaram, H; Khaw, PT; Papadopoulos, M; Pooley, F; Scawn, R; Strouthidis, NG, 2015)
" Data included patient demographics, pre- and postoperative intraocular pressure (IOP), use of mitomycin C (MMC), spacer device implantation, and follow-up details including surgical success rates."	3.81	Outcomes of combined phacoemulsification and deep sclerectomy: a 10-year UK single-centre study. ( Anand, N; Mercieca, K; Shevade, B, 2015)
"To compare the incidence of upper eyelid blepharoptosis after combined phacotrabeculectomy with mitomycin C and phacoemulsification surgeries and the relationship of bleb morphology to the incidence of ptosis."	3.81	Comparison of incidence of ptosis after combined phacotrabeculectomy with mitomycin C and phacoemulsification. ( Amrith, S; Chew, PT; Koh, V; Tatsios, J, 2015)
"Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)."	3.80	The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014)
"The aim of the present study was to evaluate the efficacy and short-term safety of topical mitomycin-C, an antifibrotic agent, in preventing the recurrence of anastomotic strictures after surgical repair of esophageal atresia (EA)."	3.80	Topical mitomycin-C application in recurrent esophageal strictures after surgical repair of esophageal atresia. ( Chapuy, L; Faure, C; Pomerleau, M, 2014)
"Twelve filtering blebs of 8 patients were included: 4 cases of trabeculectomy without mitomycin C (MMC), 6 cases of trabeculectomy with MMC, and 2 cases of non-penetrating glaucoma surgery."	3.80	[Evaluation of conjunctival epithelium of filtering blebs by impression cytology]. ( Buetas, P; González, S; López, S; Matias-Guiu, X; Muniesa, MJ; Sánchez, C, 2014)
"To evaluate the surgical outcome of Ahmed glaucoma valve (AGV) implantation with a new technique of mitomycin C (MMC) application."	3.80	Use of Mitomycin C to reduce the incidence of encapsulated cysts following ahmed glaucoma valve implantation in refractory glaucoma patients: a new technique. ( Huang, W; Wang, W; Zhang, X; Zhou, M, 2014)
"Mitomycin C (MMC), as it could reduce tissue adhesions and scar formation, has been widely adopted in pterygium surgery to lower the recurrence rate."	3.79	[Mitomycin C related complications shouldn't be neglected in the pterygium surgery]. ( Shi, WY; Wang, FH, 2013)
"To evaluate the efficacy, refractive predictability and stability, and complications of photorefractive keratectomy (PRK) with adjunctive mitomycin C (MMC) in patients with postkeratoplasty anisometropia."	3.79	Photorefractive keratectomy modification of postkeratoplasty anisometropic refractive errors. ( Goins, KM; Kitzmann, AS; Sutphin, JE; Wagoner, MD; Wandling, GR; Ward, MS, 2013)
"To report outcomes of deep sclerectomy (DS) with intraoperative mitomycin C (MMC) application in eyes with previous failed glaucoma surgery (GS) and/or cataract extraction (CE)."	3.78	Deep sclerectomy with mitomycin C in eyes with failed glaucoma surgery and pseudophakia. ( Anand, N; Wechsler, D, 2012)
"The purposes of this study were to investigate the effects of topically administrated Tacrolimus and Octreotide on modulation of postoperative scarring in experimental glaucoma filtration surgery and to compare the antifibrotic properties of these agents with mitomycin-C (MMC)."	3.78	Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery. ( Arslan, S; Aydemir, O; Dağlı, AF; Güler, M, 2012)
"Patients within an institutional setting who underwent trabeculectomy with mitomycin C (MMC) for uncontrolled elevated intraocular pressure (IOP) after corneal graft surgery were included."	3.78	Outcomes of trabeculectomy after descemet stripping automated endothelial keratoplasty: a comparison with penetrating keratoplasty. ( Boey, PY; Ho, CL; Mehta, JS; Tan, DT; Wong, TT, 2012)
"To investigate the efficacy and safety of mitomycin C (MMC)-augmented deep sclerectomy with implant (DSCI) in primary open-angle glaucoma (POAG) and exfoliation glaucoma (ExG) patients."	3.77	Mitomycin C-augmented deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma: a three-year prospective study. ( Ollikainen, ML; Puustjärvi, TJ; Rekonen, PK; Teräsvirta, ME; Uusitalo, HM, 2011)
"To investigate whether topical administration of pirfenidone eye drops could be used to prevent postoperative scarring in a rabbit model of experimental glaucoma filtration surgery."	3.77	Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. ( Lin, X; Sun, G; Wu, K; Yu, M; Zhong, H, 2011)
"To report the long-term complications and rate of local recurrence in a cohort of patients with histopathologically confirmed conjunctival melanoma (CM) treated with adjuvant topical mitomycin C (MMC)."	3.77	Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. ( Ditta, LC; Shildkrot, Y; Wilson, MW, 2011)
"Two patients experienced decreased visual acuity in 1 eye arising from elevated corneal opacity about 12 months after uneventful LASEK with intraoperative mitomycin C application."	3.77	Recurrent corneal hypertrophic scar after laser-assisted subepithelial keratectomy with mitomycin C treatment. ( Kim, DY; Kim, JH; Kim, JY; Kim, MJ; Tchah, H, 2011)
"To evaluate the safety and efficacy of using fibrin glue in cases of recurrent pterygium treated with pterygium excision and conjunctival autograft combined with mitomycin C."	3.77	Management of recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin glue. ( Boimer, C; Lee, K; Shehadeh-Mashor, R; Slomovic, AR; Srinivasan, S; Tomkins, O, 2011)
"We report on a patient with an overhanging bleb several years following trabeculectomy surgery with mitomycin C."	3.77	Dramatic dysesthetic overhanging bleb. ( Kapoor, KG; Syed, MF, 2011)
"To investigate the efficacy and safety of mitomycin C (MMC)-augmented deep sclerectomy with implant (DSCI) in patients with primary open-angle glaucoma (POAG) and exfoliation glaucoma (ExG)."	3.76	Mitomycin-C-augmented deep sclerectomy in patients with primary open-angle glaucoma and exfoliation glaucoma: a 1-year prospective study. ( Ollikainen, M; Puustjärvi, T; Rekonen, P; Teräsvirta, M; Uusitalo, H, 2010)
"Two eyes of 2 patients status postfornix-based trabeculectomy with mitomycin C were found to have symptomatic circumferential blebs."	3.76	Application of handheld cautery for reduction of symptomatic circumferential trabeculectomy blebs. ( Albano, M; Schwartz, AL, 2010)
"To determine the outcome and safety of nonlaser endonasal dacryocystorhinostomy (NLEN-DCR) with the use of adjunctive mitomycin C (MMC) in congenital, traumatic, and primary acquired nasolacrimal duct obstruction in adults."	3.76	Nonlaser endoscopic endonasal dacryocystorhinostomy with adjunctive mitomycin C in nasolacrimal duct obstruction in adults. ( Dolmetsch, AM, 2010)
"Persistent epitheliopathy, presumably resulting from limbal stem cell deficiency, is an uncommon complication of treatment of conjunctival malignant melanoma with surgical excision, cryotherapy, and mitomycin C."	3.76	Boston Ocular Surface Prosthesis for persistent epitheliopathy after treatment of conjunctival melanoma. ( Colby, KA; Grover, S; Jacobs, DS, 2010)
"To evaluate the effectiveness of intra-operative Mitomycin-C application after pterygium surgery in Irrua, Nigeria."	3.76	Effectiveness of intra-operative Mitomycin-C in reducing the recurrence of pterygium in Irrua, Nigeria. ( Dawodu, OA; Eguaoje, IE; Enock, ME; Fuh, UC; Omoti, AE, 2010)
"To report a case of necrotizing scleritis after pterygium surgery with conjunctival autografting (CA) and intraoperative Mitomycin C (MMC) and its treatment with amniotic membrane transplantation (AMT) and systemic steroid."	3.76	Successful treatment of necrotizing scleritis after conjunctival autografting for pterygium with amniotic membrane transplantation. ( Akova, YA; Borazan, M; Karalezli, A; Kucukerdonmez, C, 2010)
"To investigate the relationship between intrascleral bleb height and intraocular pressure (IOP) following deep sclerectomy with collagen implant (DSCI) and mitomycin C (MMC) in eyes with clinically flat blebs."	3.76	Postoperative IOP is related to intrascleral bleb height in eyes with clinically flat blebs following deep sclerectomy with collagen implant and mitomycin. ( Mavrakanas, N; Mendrinos, E; Shaarawy, T, 2010)
"To examine the rates of intermediate-term intraocular pressure (IOP) control after trabeculectomy with adjunctive mitomycin C (MMC) and assess for associated complications."	3.76	Primary trabeculectomy with mitomycin C: safety and efficacy at 2 years. ( Booth, F; Karim, R; Kubay, O; Lusthaus, JA; Wechsler, D, 2010)
"To assess the safety and efficacy of photorefractive keratectomy with mitomycin C (PRK-MMC) to correct refractive errors after corneal transplantation."	3.76	Photorefractive keratectomy with mitomycin C after penetrating and lamellar keratoplasty. ( Forseto, Ados S; Marques, JC; Nosé, W, 2010)
"To evaluate the safety and efficacy of deep sclerectomy with implant and mitomycin C in uveitic glaucoma."	3.75	Efficacy and safety of deep sclerectomy in uveitic glaucoma. ( Abu El-Asrar, AM; Al Obeidan, SA; Al-Muammar, AM; Osman, EA, 2009)
"02% mitomycin C (MMC) in the treatment of primary pterygium and to evaluate its safety and efficacy."	3.75	Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02% mitomycin C in primary pterygium excision. ( Cheng, LL; Lam, DS; Lam, PT; Leung, GY; Tam, PM; Young, AL, 2009)
" We compare and contrast the histopathology of a normally functioning mitomycin-C trabeculectomy site obtained from an eye enucleated for iris melanoma with abnormal blebs discussed in the literature."	3.75	Histopathology of a functioning mitomycin-C trabeculectomy. ( Lee, GA; Liang, SY; Whitehead, K, 2009)
"The protective effects of topical mitomycin-C (MMC) have been well documented for tracheal stenosis; however, to the best of our knowledge, the use of heparin as an anti-inflammatory agent to support wound healing in upper airway surgery was not studied before."	3.75	Topical heparin: a promising agent for the prevention of tracheal stenosis in airway surgery. ( Barutca, S; Derincegoz, OO; Derinceoz, OO; Meteoglu, I; Ogurlu, M; Sen, S, 2009)
"Two patients developed bleb-related ocular infection attributable to Gemella haemolysans and Gemella morbillorum after trabeculectomy with adjunctive mitomycin C."	3.75	Gemella species-associated late-onset endophthalmitis after trabeculectomy with adjunctive mitomycin C. ( Katada, T; Kawakami, H; Mikamo, H; Mochizuki, K; Sawada, A; Watanabe, K; Yamamoto, T, 2009)
"These results suggest that topical mitomycin is not effective for avoiding tracheal stenosis and may provoke the opposite effect if the dose is not carefully selected."	3.74	Effect of mitomycin in the surgical treatment of tracheal stenosis. ( González Bombardiere, S; Guilemany Toste, JM; Iñiguez-Cuadra, M; Iñiguez-Cuadra, R; Iñiguez-Sasso, R; Jofré Pavez, D; San Martín Prieto, J; Zúñiga Erranz, S, 2008)
"To retrospectively assess risk factors other than high myopia for corneal haze in patients who had conventional photorefractive keratectomy (PRK) without mitomycin-C (MMC)."	3.74	Astigmatism: risk factor for postoperative corneal haze in conventional myopic photorefractive keratectomy. ( Brunstetter, T; Rogers, S; Sheridan, MV; Thomas, KE, 2008)
"Topography-guided PRK with mitomycin C was safe and reasonably effective for the treatment of hyperopia after RK."	3.74	Customized topography-guided photorefractive keratectomy with the MEL-70 platform and mitomycin C to correct hyperopia after radial keratotomy. ( de Souza, DC; Ghanem, EA; Ghanem, RC; Ghanem, VC; Kara-José, N, 2008)
"The mid-term appearance of the filtering bleb and surgical outcome following tunnel-trabeculectomy, in which protective measures were carried out to avoid contact between the mitomycin C (MMC) and the conjunctival flap, are presented."	3.74	Protection of the conjunctival flap from contact with mitomycin C during tunnel-trabeculectomy. ( Karatas, M; Ophir, A, 2007)
"The aim of the study was to assess the outcomes of surgical revision with reopening of the scleral flap in eyes with failed glaucoma surgery and adjunctive mitomycin C (MMC)."	3.74	Surgical revision of failed filtration surgery with mitomycin C augmentation. ( Anand, N; Arora, S, 2007)
"To determine the clinical significance of postoperative conjunctival inflammation noted at the third or fourth week after intraoperative application of mitomycin C and amniotic membrane transplantation for pterygium."	3.74	Role of conjunctival inflammation in surgical outcome after amniotic membrane transplantation with or without fibrin glue for pterygium. ( Casas, V; Kheirkhah, A; Raju, VK; Sheha, H; Tseng, SC, 2008)
"The role of topically applied mitomycin C in preventing postoperative perineural fibrosis was examined by gross anatomical dissection and histological analysis in rats."	3.73	Topical application of mitomycin C prevents epineural scar formation in rats. ( Ceylan, S; Etus, V; Ilbay, G; Ilbay, K; Yildiz, K, 2005)
"To report the experience with trabeculectomy augmented with mitomycin C and 5-fluorouracil for the treatment of paediatric glaucoma."	3.73	Augmented trabeculectomy in paediatric glaucoma. ( Ehrlich, R; Friling, R; Gaton, DD; Lusky, M; Snir, M; Weinberger, D, 2005)
"To investigate the comparative efficacy and safety of deep sclerectomy with and without intraoperative mitomycin C (MMC) application for lowering the intraocular pressure (IOP)."	3.73	Deep sclerectomy augmented with mitomycin C. ( Anand, N; Atherley, C, 2005)
"The routine use of mitomycin C to enhance glaucomatous filtering surgery has found wide acceptance."	3.73	Bullous keratopathy as a complication of trabeculectomy with mitomycin C. ( Krieglstein, GK; Mietz, H; Roters, S, 2005)
"To conduct a pilot study evaluating the efficacy and safety of limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C treatment for recurrent pterygium."	3.73	Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium. ( Amano, S; Hara, R; Miyai, T; Miyata, K; Nejima, R; Yonemura, T, 2005)
"To report a case of postoperative cystic epithelial downgrowth treated with needle aspiration and intralesional administration of mitomycin C."	3.73	Treatment of cystic epithelial downgrowth with intralesional administration of mitomycin C. ( Chiu, SI; Tse, RK; Yu, CS, 2005)
"To prospectively study the evolution of possible high risk features of conjunctival filtration blebs like avascularity, transconjunctival oozing (TCO), and leaks after mitomycin C (MMC) enhanced glaucoma surgery."	3.73	Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. ( Anand, N; Arora, S; Clowes, M, 2006)
"Antimetabolites, especially mitomycin C (MMC), increase the incidence of late bleb-related endophthalmitis in trabeculectomy."	3.73	Determinants of bleb morphology in minimally invasive, clear-cornea micropenetrating glaucoma surgery with mitomycin C. ( Flesner, P; Jensen, PK; Kessing, SV, 2006)
"To report a patient with dry eye after bilateral photorefractive keratectomy (PRK) with mitomycin C treatment in one eye."	3.73	Dry eye after photorefractive keratectomy with adjuvant mitomycin C. ( Diakonis, VF; Ginis, H; Kymionis, GD; Pallikaris, I; Tsiklis, NS, 2006)
"To determine the long-term intraocular pressure (IOP) control and postoperative complications after initial trabeculectomy with use of mitomycin C (MMC) in patients with primary open-angle glaucoma (POAG)."	3.73	Long-term follow-up of initial trabeculectomy with mitomycin C for primary open-angle glaucoma in Japanese patients. ( Araie, M; Chen, YN; Shigeeda, T; Shirato, S; Tomidokoro, A, 2006)
"Mitomycin C in appropriate dose minimizes postoperative fibrosis and granulations, thereby maintaining a bigger postoperative ostium throughout the postoperative observation period."	3.73	Effect of mitomycin C on ostium in dacryocystorhinostomy. ( Barua, CK; Bhattacharjee, H; Bhattacharjee, K; Bhuyan, SK; Deka, A; Khaund, G, 2006)
"To report a case of scleral melting noted 16 years after pterygium excision with postoperative adjuvant topical Mitomycin C (MMC)."	3.73	Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. ( Azwa, JA; Ibrahim, M; Raihan, IS; Wan Norliza, WM, 2006)
"To determine the outcomes of trabeculectomy with mitomycin C (MMC) combined with direct cauterization of peripheral iris before iridectomy in the management of neovascular glaucoma (NVG), and to demonstrate the effect of this surgical technique on decreasing the incidence of intraoperative bleeding and early postoperative hyphema."	3.73	Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. ( Batman, A; Berker, N; Cankaya, B; Elgin, U; Simsek, T, 2006)
"With adequate inflammation suppression, phacotrabeculectomy with mitomycin C is an effective and safe therapeutic option for the management of secondary cataract and glaucoma in uveitic eyes."	3.73	Phacotrabeculectomy with mitomycin C in patients with uveitis. ( Ahn, JK; Park, KH; Park, UC; Yu, HG, 2006)
"To evaluate the efficacy of "straight scleral tunnel incision" -trabeculectomy with a releasable suture supplemented with mitomycin C (MMC) on reducing intraocular pressure (IOP), complications, and corneal astigmatism in patients with primary angle-closure glaucoma (PACG)."	3.73	Mitomycin C "straight scleral tunnel incision"--trabeculectomy with a releasable suture. ( Chen, LX; Fang, F; Tang, H; Wang, LN; Xiao, L; Zhang, Y; Zhao, TH, 2006)
"The aim of this study was to evaluate the effectiveness and safety of combining application of mitomycin and/or amnion transplantation when carrying out pterygium resection."	3.73	[Clinical study in combining application of mitomycin and amnion transplantation together with pterygium resection]. ( Huang, Y; Wang, B; Ye, Q, 2005)
"The present findings indicate that the additional use of mitomycin C may be justified in trabeculectomies in patients with severe glaucoma."	3.72	Five-year results of trabeculectomy with mitomycin C. ( Beckers, HJ; Kinders, KC; Webers, CA, 2003)
"Immediate adjuvant Mitomycin C (MMC) instillation is routine practice in the treatment of superficial bladder cancer."	3.72	Unusual complication after immediate postoperative intravesical mitomycin C instillation. ( Bex, A; Horenblas, S; Nieuwenhuijzen, JA, 2003)
"In this prospective interventional case series of 45 consecutive uncomplicated glaucoma patients, 45 eyes with thick Tenon's capsule underwent primary trabeculectomy with intraoperative mitomycin-C (0."	3.72	Effects of thick Tenon's capsule on primary trabeculectomy with mitomycin-C. ( Akarsu, C; Hasanreisoglu, B; Onol, M, 2003)
"Sixteen (80%) of 20 cases developed severe scleral necrosis that required tectonic surgery after bare sclera pterygium excision with mitomycin C or beta-irradiation."	3.72	Tectonic corneal lamellar grafting for severe scleral melting after pterygium surgery. ( Tan, DT; Ti, SE, 2003)
"To assess the role of mitomycin C (MMC) in the management of pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction."	3.72	Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. ( Annino, DJ; Goguen, LA, 2003)
"Mitomycin C (MMC) used as an additive agent in glaucoma surgery has been shown to improve the postoperative results of intraocular pressure (IOP), but may also lead to higher incidences of postoperative wound healing disorders and of hypotonia with choroidal detachment."	3.72	[Clinical experiences and results of application of mitomycin C in trabeculectomy]. ( Hudde, T; Laube, T; Ritters, B; Selbach, M, 2003)
"Comparison of fornix- and limbus-based conjunctival flaps with respect to cystic bleb-related complications of trabeculectomy with high-dose mitomycin C (MMC) in pediatric and young adult glaucoma."	3.72	Cystic bleb formation and related complications in limbus- versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. ( Bunce, C; Cordeiro, MF; Khaw, PT; Wells, AP, 2003)
"To investigate the influence of 5-fluorouracil (5-FU) and mitomycin C (MMC) on the postoperative adhesions following strabismus surgery in rabbits."	3.72	Effects of intraoperative sponge mitomycin C and 5-fluorouracil on scar formation following strabismus surgery in rabbits. ( Düzcan, E; Eşme, A; Ozden, S; Tatlipinar, S; Yaylali, V; Yildirim, C, 2004)
"To evaluate long term complications after pterygium excision with mitomycin C (MMC) application."	3.72	Mitomycin C for pterygium: long term evaluation. ( Frucht-Pery, J; Ilsar, M; Landau, D; Raiskup, F; Solomon, A, 2004)
"The authors performed a nonrandomized retrospective review of patients who received the Molteno implant (n = 27), Krupin Eye Valve with Disc (n = 13), or Ahmed Glaucoma Valve (n = 13), with adjunctive mitomycin C."	3.71	Comparison of the Ahmed Glaucoma Valve, the Krupin Eye Valve with Disk, and the double-plate Molteno implant. ( Gangnon, R; Heatley, GA; Kaufman, PL; Perkins, TW; Taglia, DP, 2002)
"To describe the surgical technique and clinical outcomes of a procedure for refractory glaucoma, concurrent Baerveldt glaucoma implant (BGI) and trabeculectomy with mitomycin C."	3.71	Combined Baerveldt glaucoma drainage implant and trabeculectomy with mitomycin C for refractory glaucoma. ( Budenz, DL; Bueche, M; Feuer, W; Nguyen, QH; Nicolela, MT; Palmberg, PF; Scott, IU; Singh, K, 2002)
"Bleb leakage occurred in 14 eyes following trabeculectomy (mitomycin C treatment, 10 eyes; 5-fluorouracil treatment, 3 eyes; no antifibrosis agent, 1 eye) and in 1 eye following combined cataract and glaucoma surgery with adjunctive mitomycin C therapy."	3.70	Late-onset bleb leaks after glaucoma filtering surgery. ( Greenfield, DS; Jee, J; Liebmann, JM; Ritch, R, 1998)
"To determine whether intrascleral exposure to mitomycin-C (MMC) improves the control of intraocular pressure (IOP), increases the incidence of complications, or both."	3.70	Episcleral versus combined episcleral and intrascleral application of mitomycin-C in trabeculectomy. ( Menapace, R; Rainer, G; Strenn, K; Vass, C, 1998)
"The purpose of this study was to determine the efficacy of initial mitomycin C (MMC)-augmented trabeculectomy for uncomplicated glaucoma in young patients."	3.70	Adjunctive mitomycin C in primary trabeculectomy in young adults: a long-term study of case-matched young patients. ( Dietlein, TS; Jacobi, PC; Krieglstein, GK, 1998)
"Retrospective review of consecutive cases of pediatric glaucoma that underwent mitomycin C augmented trabeculectomy between January 1991 and December 1995."	3.70	Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. ( Beck, AD; Lynch, MG; Lynn, MJ; Noe, R; Wilson, WR, 1998)
"To evaluate the surgical results and complications of mitomycin C-augmented trabeculectomy in refractory developmental glaucoma."	3.70	Surgical results and complications of mitomycin C-augmented trabeculectomy in refractory developmental glaucoma. ( Mandal, AK; Naduvilath, TJ; Prasad, K, 1999)
"The use of adjunctive antimetabolites such as 5-fluorouracil (5-FU) and mitomycin C (MMC) in trabeculectomy has caused an increased concern as to the risk of bleb-associated endophthalmitis."	3.70	Late-onset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. ( Frucht-Pery, J; Solomon, A; Ticho, U, 1999)
"To evaluate the effectiveness and safety of trabeculectomy with mitomycin-C (MMC) in the management of childhood glaucomas."	3.70	Trabeculectomy with mitomycin-C in the treatment of pediatric glaucomas. ( Belmonte, SJ; Liebmann, JM; Ritch, R; Sidoti, PA, 2000)
"Mitomycin C has improved the success rate of glaucoma filtering surgery in patients at high risk for surgical failure."	3.70	Midterm follow-up of necrotic bleb excision and advancement of the fornical conjunctiva. ( Ahn, DG; Hyung, SM, 1999)
"To evaluate the efficiency of mitomycin C (MMC) in limiting the postoperative inflammatory response and scarring after strabismus surgery."	3.70	Histologic effect of mitomycin C on strabismus surgery in the rabbit. ( Akaishi, PM; De Luca, IM; Minguini, N; Monteiro de Carvalho, KM, 2000)
"A concurrent series (from January 1, 1987, to October 1, 1997) of one surgeon's consecutive 585 (456 patients) combined cataract extraction, intraocular lens implantation, and trabeculectomy surgeries, some with intraoperative mitomycin C and/or postoperative subconjunctival 5-fluorouracil."	3.70	Outcomes of combined cataract extraction, lens implantation, and trabeculectomy surgeries. ( Hahn, J; Larive, B; Rockwood, EJ, 2000)
"Adjunctive chemotherapy with Mitomycin C (MMC) has been used in an attempt to modulate the wound healing response in glaucoma filtration surgery."	3.69	Success rate and complications of intraoperative 0.2 mg/ml mitomycin C in trabeculectomy surgery. ( Chawla, HB; O'Brien, C; Singh, J, 1995)
"Twenty-one eyes of 21 patients with refractory glaucoma underwent glaucoma surgery involving placement of a modified Molteno implant and intraoperative application of mitomycin C."	3.69	Mitomycin C as adjunctive therapy with glaucoma implant surgery. ( Nicolela, MT; Susanna, R; Takahashi, WY, 1994)
"Mitomycin C (MMC) was used as a perioperative adjunct during trabeculectomy for 51 consecutive cases of complicated glaucoma."	3.69	Mitomycin C for trabeculectomy in complicated glaucoma: preliminary results after 6 months. ( Krieglstein, GK; Mietz, H, 1994)
"To evaluate intraocular pressure (IOP) control and surgical complications following trabeculectomy with 5-fluorouracil (5-FU) or mitomycin at the inferior limbus."	3.69	Trabeculectomy at the inferior limbus. ( Caronia, RM; Cohen, H; Friedman, R; Liebmann, JM; Ritch, R, 1996)
"To determine whether filtering blebs resulting from adjunctive use of mitomycin C (MMC) leads to an increased risk of endophthalmitis."	3.69	Bleb-related endophthalmitis after trabeculectomy with mitomycin C. ( Bergstrom, TJ; Higginbotham, EJ; Karp, KO; Lichter, PR; Musch, DC; Skuta, GL; Stevens, RK, 1996)
"Administration of subconjunctival 5-fluorouracil (5-FU) and topical mitomycin-C (MMC) has been shown to improve the success rate of glaucoma-filtering surgery."	3.69	A novel MMC-loaded pHEMA drainage device for the treatment of glaucoma: in vitro and in vivo studies. ( Akata, RF; Gökçe, M; Kiremitçi-Gümüşderelioglu, M, 1996)
"The purposes of this study are to examine the complications and results of a novel approach to the use of mitomycin-C in pterygium surgery; to identify the lowest effective dosage required to prevent recurrence; and to select those high-risk pterygia that could benefit from mitomycin-C use."	3.69	Indications for and complications of mitomycin-C in pterygium surgery. ( Anduze, AL; Burnett, JM, 1996)
"To evaluate acute retinal vein occlusion as a potential complication of trabeculectomy with mitomycin C in cases of advanced glaucoma."	3.69	Retinal vein occlusion after trabeculectomy with mitomycin C. ( Dev, S; Herndon, L; Shields, MB, 1996)
"Both large- and small-incision phacoemulsification, intraocular lens implant, and trabeculectomy with intraoperative Mitomycin-C provide good intermediate range (1 year) postoperative IOP in eyes with coexisting cataract and glaucoma."	3.69	Combined phacoemulsification, intraocular lens implant, and trabeculectomy with intraoperative mitomycin-C: comparison between 3.2- and 6.0-mm incisions. ( Wand, M, 1996)
"Combined penetrating keratoplasty and trabeculectomy with mitomycin-C should be considered for selected patients with uncontrolled glaucoma and corneal disease who have sufficient conjunctiva for a filtering procedure."	3.69	Management of coexisting corneal disease and glaucoma by combined penetrating keratoplasty and trabeculectomy with mitomycin-C. ( Araujo, SV; Cohen, EJ; Figueiredo, RS; Katz, LJ; Rapuano, CJ; Wilson, RP, 1996)
"To determine the surgical outcome of mitomycin trabeculectomy in patients with refractory glaucoma."	3.69	Surgery for refractory glaucoma. ( Hagiwara, Y; Kitazawa, Y; Sawada, A; Yamamoto, T, 1996)
"The records of 157 eyes of 157 consecutive patients, aged 18 or older, who underwent mitomycin C trabeculectomies for uncontrolled glaucoma of various causes were reviewed."	3.69	Intermediate-term outcome of variable dose mitomycin C filtering surgery. ( Cheung, JC; Murali, S; Pederson, JE; Wright, MM, 1997)
"The authors studied the effect of topical mitomycin-C administration on the maintenance of filter function and intraocular pressure (IOP) following laser sclerostomy."	3.69	Mitomycin-C in laser sclerostomy: benefit and complications. ( Birngruber, R; Dröge, G; Schmidt-Erfurth, U; Wetzel, W, 1997)
" Combined phacoemulsification and mitomycin C trabeculectomy appears to be safe and effective for treating selected patients with coexisting glaucoma and cataract."	3.69	Limbus- versus fornix-based conjunctival flaps in combined phacoemulsification and mitomycin C trabeculectomy surgery. ( Berestka, JS; Brown, SV, 1997)
"This study demonstrated that mitomycin has a significant inhibitory effect on secondary cataract formation (proliferation as well as fibrosis) in rabbits whereas heparin does not seem to have the same effectiveness."	3.69	Mitomycin against posterior capsular opacification: an experimental study in rabbits. ( Galand, AL; Haus, CM, 1996)
"Twenty-nine consecutive eyes of 26 patients with cataract and glaucoma that had undergone combined phacoemulsification, posterior chamber lens implantation, and limbus-based trabeculectomy with mitomycin-C applied after the cataract removal and trabeculectomy had a minimal follow-up time of 12 months (mean follow-up 20 +/- 6."	3.69	Midterm follow-up results of combined phacoemulsification, lens implantation, and mitomycin-C trabeculectomy procedure. ( Belyea, DA; Dan, JA; Lieberman, MF; Stamper, RL, 1997)
"The authors studied the efficacy and complications of intraoperative mitomycin-C in glaucoma associated with ocular inflammation."	3.69	Intraoperative mitomycin-C for glaucoma associated with ocular inflammation. ( McGehee, RF; Pederson, JE; Wright, MM, 1997)
"The purpose of the study is to determine the safety and efficacy of mitomycin C-augmented trabeculectomy in children with developmental glaucoma treated previously by conventional procedures."	3.69	Mitomycin C-augmented trabeculectomy in refractory congenital glaucoma. ( Jayagandan, A; John, T; Mandal, AK; Walton, DS, 1997)
"To evaluate the effectiveness of combined phacoemulsification and trabeculectomy with mitomycin-C with respect to visual rehabilitation and control of intraocular pressure in patients with coexisting cataract and glaucoma."	3.69	Combined phacoemulsification and trabeculectomy with mitomycin-C. ( Schuman, JS; Zacharia, PT, 1997)
"(1) Since the interval between reoperation and intraocular pressure increase was very short in all cases, overfiltration is at least one major reason for hypotony, not only ciliary body failure; (2) in cases of persistent hypotony after filtering surgery with mitomycin C, surgical reintervation can be recommended."	3.69	[Surgical revision for hypotonia after glaucoma operation with mitomycin C]. ( Funk, J, 1997)
"To evaluate the safety and efficacy of trabeculectomy with mitomycin-C in the management of postkeratoplasty glaucoma."	3.69	Trabeculectomy with mitomycin-C for postkeratoplasty glaucoma: a preliminary study. ( Gupta, A; Kumar, S; Ram, J; Sharma, A, 1997)
"The clinical appearance of cystic blebs and the incidence of bleb infection were retrospectively evaluated in 215 trabeculectomies with mitomycin C."	3.69	[The long-term cystic bleb appearance and safety after trabeculectomy with mitomycin C]. ( Kadowaki, H; Kuroda, S; Matsumura, M; Mizoguchi, T; Nagata, M; Terauchi, H, 1997)
"The purpose of the study is to assess the effect of adjunctive intraoperative mitomycin C (MMC) in Molteno drainage device implantation for patients with recalcitrant glaucomas."	3.69	The effect of adjunctive mitomycin C in Molteno implant surgery. ( Birt, CM; Khatana, AK; Kim, C; Kupin, TH; Lee, D; Olivier, MM; Reed, SY; Shin, DH, 1997)
"To evaluate the outcome of Baerveldt implantation with adjunctive mitomycin-C in cases of complicated glaucoma."	3.69	Simultaneous use of mitomycin-C with Baerveldt implantation. ( Azuara-Blanco, A; Moster, MR; Schmidt, CM; Wilson, RP, 1997)
"To determine whether 5-fluorouracil is effective in reducing scarring after strabismus surgery we used rectus muscle surgery in experimental animals to compare a single intraoperative dose of 5-fluorouracil with mitomycin C and to compare results in similarly treated controls not receiving these antimetabolites."	3.69	Intraoperative sponge 5-fluorouracil to reduce postoperative scarring in strabismus surgery. ( Evan, AP; Helveston, EM; Mora, JS; Sprunger, DT, 1997)
"In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed."	3.68	A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993)
" Thirty-three months before, the patient had a pterygium excised and mitomycin C, 0."	3.68	Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. ( Fujitani, A; Hayasaka, S; Noda, S; Shibuya, Y, 1993)
"The use of topical mitomycin (mitomycin-C) as a medical adjunct to pterygium and glaucoma surgery is increasing."	3.68	Serious complications of topical mitomycin-C after pterygium surgery. ( Foster, CS; Martin, NF; Pfister, RR; Rubinfeld, RS; Speaker, MG; Stein, RM; Stoleru, S; Talley, AR, 1992)
"Right corneal melting and scleral necrosis developed in a 77-year-old man 5 months after pterygium excision followed by topical administration of mitomycin C drops (0."	3.68	Corneal melting after pterygium removal followed by topical mitomycin C therapy. ( Climenhaga, DB; Ewing-Chow, DA; Gilmour, GR; Romanchuk, KG; Underhill, JH, 1992)
"Patients with primary open angle glaucoma, not controlled with medication, were selected from the outpatient department."	2.87	Comparison of Mean Corneal Endothelial Cell Loss after Trabeculectomy with and without Mitomycin C. ( Ahmed, N; Amjad, A; Shaheer, M, 2018)
"Mean intraocular pressure was significantly reduced compared with baseline in both groups (P < 0."	2.79	Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). ( Ahmed, II; Condon, G; Moster, MR; Netland, PA; Salim, S; Sarkisian, SR; Sherwood, MB; Siegfried, CJ, 2014)
"To compare the recurrence of pterygium between free conjunctival auto-graft and conjunctival rotation flap following simple surgical excision of pterygium."	2.79	Reducing postoperative pterygium recurrence: comparison of free conjunctival auto-graft and conjunctival rotation flap techniques. ( Akhter, W; Kausar, A; Masrur, A; Tayyab, A, 2014)
"At 6 months postoperatively, the recurrence rate of pterygium was 5."	2.78	Observation of long-term efficacy of corneal limbal conjunctival autografts in microscopy treatments of pterygium. ( Pi, M; Xu, F; Yang, Y, 2013)
"We found more pterygium recurrences in the MMC group."	2.78	[Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study]. ( Bouguila, H; Boujemaa, C; Chebbi, A; Lajili, Z; Malek, I; Nacef, L; Saida Ayed, S; Zghal, I, 2013)
"New-onset persistent diplopia was reported in 5 patients (5%) in the tube group and no patients in the trabeculectomy group at 1 year (P = ."	2.74	Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up. ( Barton, K; Feuer, WJ; Gedde, SJ; Lee, RK; Rauscher, FM; Schiffman, JC, 2009)
"Mitomycin C (MMC) is an antibiotic-antineoplastic agent that decreases fibroblast proliferation and scar formation."	2.72	Effect of mitomycin C on the size of antrostomy after endoscopic sinus surgery. ( Cha, HE; Chung, YS; Gang, IG; Ha, JS; Kim, ST, 2006)
"To study the clinical effect of trabeculectomy combined with Mitomycin C and removed suture."	2.71	[Trabeculectomy combined with mitomycin C and removed suture in glaucoma]. ( Feng, Y, 2003)
"Patients were followed for recurrence (defined as fibrovascular tissue invading the cornea >1."	2.71	A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium. ( Cheng, LL; Lam, DS; Leung, GY; Wong, AK; Young, AL, 2004)
"The intraocular pressure was significantly decreased by 7."	2.70	Primary deep sclerectomy versus primary deep sclerectomy with the use of mitomycin C in primary open-angle glaucoma. ( Christodoulakis, EV; Kozobolis, VP; Pallikaris, IG; Tzanakis, N; Zacharopoulos, I, 2002)
"Mitomycin C (MMC) is an antineoplastic agent that has been shown to decrease scar tissue after ophthalmologic surgery."	2.70	Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study. ( Chung, JH; Cosenza, MJ; Metson, RB; Rahbar, R, 2002)
"Two hundred forty-eight gastric cancer patients thought to have resectable cancer were randomized intraoperatively to receive EPIC with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5 versus surgery only."	2.69	Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. ( Averbach, A; Chang, D; Sugarbaker, PH; Whang, I; Yu, W, 1998)
" Combining the use of MMC with conjunctival autograft allows for decreased dosage and time of intraoperative exposure of mitomycin, thereby making it safer for application."	2.69	Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians. ( Law, FC; Wong, VA, 1999)
"5-Fluorouracil and MMC were found to be equally safe and effective adjuncts to primary trabeculectomy in the short- and medium-term postoperative periods."	2.69	Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. ( Baerveldt, GS; Budenz, DL; Chen, PP; Cohen, JS; Greenfield, DS; Mehta, K; Moster, MR; Shaikh, NM; Shaikh, S; Singh, K; Tsai, JC, 2000)
"To determine the rate of recurrence and complications after bare sclera excision of primary pterygia followed by low-dose mitomycin C (0."	2.68	A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. ( Ariyasu, RG; Chen, PP; Kaza, V; LaBree, LD; McDonnell, PJ, 1995)
"Late postoperative complications are similar with the exception of an increased incidence of Tenon cyst formation in the MMC-treated eyes."	2.68	Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. ( Bergstrom, TJ; Higginbotham, EJ; Johnson, AT; Katz, GJ; Lichter, PR; Musch, DC; Skuta, GL, 1995)
"Mitomycin was applied for 5 minutes only once during trabeculectomy."	2.67	Low-dose and high-dose mitomycin trabeculectomy as an initial surgery in primary open-angle glaucoma. ( Kawase, K; Kitazawa, Y; Suemori-Matsushita, H; Yamamoto, T, 1993)
"After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy."	2.67	[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990)
" Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful."	2.65	[Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)]. ( Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982)
"Mitomycin C (MMC) was introduced as a healing modulator and applied on the corneal surface after refractive surgery to address these drawbacks."	2.61	A Critical Overview of the Biological Effects of Mitomycin C Application on the Cornea Following Refractive Surgery. ( Arranz-Marquez, E; Katsanos, A; Konstas, AGP; Kozobolis, VP; Teus, MA, 2019)
"The objective of this study was to evaluate the efficacy and safety of bevacizumab combined with antimetabolite as an adjunctive therapy in primary trabeculectomy for glaucoma."	2.58	Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials. ( Chen, HJ; Chen, YH; Lee, CH; Lin, C, 2018)
"As the prevalence of liver cancer increases, so does the demand for nonsurgical, minimally invasive alternatives to surgery, since many patients have tumors that cannot be surgically resected."	2.52	Catheter-based transarterial therapies for hepatocellular cancer. ( Laroia, AT; Laroia, ST; Morales, SA, 2015)
" The optimum route of administration and dosing regimen of anti-VEGF antibodies and their positioning in comparison with 5-fluorouracil and mitomycin C are uncertain."	2.47	Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery. ( Barton, K; Mathew, R, 2011)
"However, the recurrence is still an unsolved problem."	2.46	Clinical findings and treatments of granular corneal dystrophy type 2 (avellino corneal dystrophy): a review of the literature. ( Choi, SI; Chung, WS; Han, KE; Kim, BY; Kim, EK; Kim, TI, 2010)
"Mitomycin C was not used in the field of otolaryngology before 1998."	2.42	Use of mitomycin C in the pediatric airway. ( Senders, CW, 2004)
"Treatment of leakage with ocular hypotony after trabeculectomy with mitomycin C (MMC) can be safely achieved through conjunctival patch alone or combined with donor scleral graft in cases of melted underlying sclera."	1.62	Outcome of Bleb Revision With Autologous Conjunctival Graft Alone or Combined With Donor Scleral Graft for Late-onset Bleb Leakage With Hypotony After Standard Trabeculectomy With Mitomycin C. ( Chronopoulos, P; Grehn, F; Hoffmann, EM; Laspas, P; Peters, H; Pfeiffer, N; Prokosch-Willing, V; Wahl, J, 2021)
"Mitomycin-C (MMC) was used in 20% and oxaliplatin in 10%."	1.56	Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. ( Ashwin, KR; Kumar C, R; Rauthan, A; Somashekhar, SP; Yethadka, R; Zaveri, S, 2020)
" The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs."	1.56	Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. ( Chen, LF; Ji, ZH; Li, XB; Li, Y; Lin, YL; Ma, R; Yan, FC; Yang, ZR; Zhang, J, 2020)
"Treatment of tracheal stenosis is occasionally performed in combination with wound healing modulators to manipulate new extracellular matrix (ECM) formation and prevent fibrosis."	1.56	Treatment with Hyaluronic Acid and Collagen-Polyvinylpyrrolidone Improves Extracellular Matrix Assembly for Scarring after Tracheal Resection. ( Baltazares-Lipp, M; Baltazares-Lipp, ME; Gaxiola-Gaxiola, M; González-González, AI; Hernández-Jiménez, C; Iñiguez-García, MA; Jasso-Victoria, R; Luna-Flores, A; Olmos-Zuñiga, JR; Silva-Martínez, M; Solis-Alanis, N; Vázquez-Minero, JC, 2020)
"Low postoperative complications were recorded."	1.56	Penetrating deep sclerectomy in primary open-angle and pseudoexfoliative glaucoma. ( Kalogianni, E; Kozobolis, V; Sideroudi, H, 2020)
"This study is the largest series reported showing that topical application of MC is an efficient and safe treatment for recurrent esophageal stenosis in children."	1.51	Efficacy and Safety of the Local Application of Mitomycin C to Recurrent Esophageal Strictures in Children. ( Bridenne, M; Fayoux, P; Gottrand, F; Hauser, B; Lachaux, A; Lemale, J; Ley, D; Michaud, L; Rebouissoux, L; Viala, J, 2019)
"Persistent congenital nasolacrimal duct obstruction refractory to earlier interventions of probing or intubation was the most common indication for the surgery noted in 57% (77/135)."	1.51	Outcomes in paediatric external dacryocystorhinostomy: a single-centre experience. ( Ali, MJ; Dave, TV; Ezeanosike, E; Naik, MN, 2019)
"Mitomycin C (MMC) has been utilized for its antifibrotic properties in nonmalignant tracheobronchial stenosis but its application is not well studied in post-lung transplant stenosis."	1.51	Management of Lung Transplant Bronchial Stenosis With Mitomycin C. ( Cheng, GZ; Davidson, KR; Elmasri, M; Mahmood, K; Shofer, SL; Wahidi, MM, 2019)
"Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)."	1.48	Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018)
"Mitomycin C was used in 15/19 eyes."	1.46	Intermediate Term Outcomes of Early Posttrabeculectomy Bleb Leaks Managed by Large Diameter Soft Bandage Contact Lens. ( Garudadri, CS; Gollakota, S; Mohamed, A; Senthil, S, 2017)
" No adverse events were reported."	1.46	Mitomycin-C and urethral dilatation: A safe, effective, and minimally invasive procedure for recurrent vesicourethral anastomotic stenoses. ( Bettez, M; Jundi, M; Richard, PO; Sourial, MW; Tu, LM, 2017)
"Main postoperative complications were transient: 4 eyes with seidel phenomenon at 24 hours (10."	1.46	Two-year Results After Deep Sclerectomy With Nonabsorbable Uveoscleral Implant (Esnoper-Clip): Surgical Area Analysis Using Anterior Segment Optical Coherence Tomography. ( Castellvi-Manent, J; Loscos-Arenas, J; Moll-Udina, A; Romanic-Bubalo, N; Romera-Romero, P; Valldeperas, X, 2017)
"Trabeculectomy is a safe and effective method for achieving single-digit IOP targets in NTG eyes with progression at low IOP."	1.43	Safety And Efficacy Of Achieving Single-Digit Intraocular Pressure Targets With Filtration Surgery In Eyes With Progressive Normal-Tension Glaucoma. ( Greenfield, DS; Iverson, SM; Schultz, SK; Shi, W, 2016)
"The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox."	1.43	Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. ( Charrier, T; Cotte, E; Elias, D; Eveno, C; Glehen, O; Gocevska, S; Goere, D; Maurice, C; Ortega-Deballon, P; Passot, G; Peron, J; Pocard, M; Quénet, F; Vaudoyer, D, 2016)
"Three procedures (6%) had intraoperative complications (2 iris prolapses, 1 subconjunctival hemorrhage)."	1.43	Medium-term Outcomes of Unsutured Scleral Flap Trabeculectomies. ( Ang, GS; Meagher, P; Wang, BZ, 2016)
"To report the 5-year incidence of visual impairment after mitomycin C-augmented trabeculectomy (MMC trabeculectomy) and the risk factors for visual impairment."	1.43	Change in visual acuity and associated risk factors after trabeculectomy with adjunctive mitomycin C. ( Araie, M; Chiba, T; Kashiwagi, K; Kogure, S; Kuwayama, Y; Mabuchi, F; Yamamoto, T, 2016)
"To evaluate the visual outcomes, recurrence patterns, safety, and efficacy of excimer laser phototherapeutic keratectomy (PTK) in conjunction with mitomycin C (MMC) for corneal macular and granular diystrophies."	1.43	Excimer laser phototherapeutic keratectomy in conjunction with mitomycin C in corneal macular and granular dystrophies. ( Bilgihan, K; Cubuk, MO; Eroglu, HY; Yuksel, E, 2016)
"Refractory esophageal stenosis (RES) is a major health problem in the pediatric population."	1.43	Management of refractory esophageal stenosis in the pediatric age. ( Alberca de Las Parras, F; Egea Valenzuela, J; Navalón Rubio, M, 2016)
"To determine the efficacy of safe surgery system trabeculectomy combined with manual small incision cataract surgery/phacoemulsification in primary glaucoma coexistent with cataract."	1.42	Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction. ( Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015)
"Forty-eight eyes of 41 patients with open angle glaucoma (OAG), who underwent DS with supraciliary hema implant (Esnoper(®) V-2000), were included in this study."	1.42	Deep sclerectomy with supraciliary hema implant (Esnoper® V-2000): results and complications. ( de la Cámara, J; Langhor, K; Langohr, K; Loscos, J; Parera, À; Romera, P; Sabala, A; Valldeperas, X, 2015)
"In patients undergoing colorectal cancer surgery, skeletal muscle depletion (sarcopenia) is associated with impaired postoperative recovery and decreased survival."	1.42	Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. ( Boerma, D; Bollen, TL; Braam, HJ; de Hingh, IH; van Oudheusden, TR; van Ramshorst, B; van Vugt, JL; Vestering, A; Wiezer, MJ, 2015)
"Postoperative endophthalmitis is a devastating complication after trabeculectomy."	1.40	Endophthalmitis and severe blebitis following trabeculectomy. Epidemiology and risk factors; a single-centre retrospective study. ( Al-ahramy, AM; Lundström, M; Montan, P; Wallin, Ö, 2014)
"Mitomycin was applied in 15 patients."	1.40	Early endoscopic dilation and mitomycin application in the treatment of acquired tracheal stenosis. ( Castro, L; De la Serna, O; De La Torre, C; Dominguez, E; Encinas, JL; Hernandez, F; Lopez-Fernandez, S; Menendez, JJ; Ortiz, R; Santamaria, ML; Tovar, JA; Vazquez, J, 2014)
"Among the CRC and appendiceal cancer group the median overall survival was 20."	1.40	[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. ( Aderka, D; Berger, Y; Brenner, B; Golan, T; Gutman, M; Lebedyev, A; Levi, Y; Natur, M; Nevler, A; Purim, O; Zbar, AP, 2014)
"MMC-augmented revision appears to be a safe and useful tool in reducing intraocular pressure after trabeculectomy failure."	1.39	Efficacy and safety of mitomycin C--augmented revisions of non-functioning filtering blebs after trabeculectomy--7 year results. ( Kosior-Jarecka, E; Tomaszewska, J; Tulidowicz-Bielak, M; Zarnowski, T, 2013)
"The frequency of LT1009 dosage was determined initially using an enzyme-linked immunosorbent assay assay measuring LT1009 eye tissue retention in 6 New Zealand White rabbits."	1.39	Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model. ( Beattie, AR; Levine, MA; Lukowski, ZL; Meyers, CA; Min, J; Samuelson, DA; Schultz, GS; Sherwood, MB; Stoller, G, 2013)
"Mitomycin-C has been in clinical use primarily as a chemotherapeutic agent and is well known for antifibrotic properties."	1.39	The effect of mitomycin-C in reducing pericardial adhesion after cardiac surgery in rabbits. ( Akkaya, IO; Aksoy, ON; Alpay, MF; Bayrak, R; Cakir, O; Colak, N; Nazli, Y; Tasoglu, I, 2013)
"Mitomycin C was not effective in preventing middle meatus synechia, but reduced the probability of total synechia formation."	1.38	The use of Mitomycin-C to reduce synechia in middle meatus in sinus surgery: preliminary results. ( Gregório, LC; Yamaoka, WY, 2012)
"Needling revision with adjunctive MMC is effective for reviving flat filtering blebs and controlling IOP, even several years after the original trabeculectomy, and seems to be safe for the corneal endothelium."	1.37	Late needling of flat filtering blebs with adjunctive mitomycin C: efficacy and safety for the corneal endothelium. ( Cronemberger, S; Diniz, AF; Ferreira, GA; Filho, AD; Maestrini, HA; Matoso, HD; Mérula, RV; Reis, JR; Sakurai, E, 2011)
"Anal stricture is a well-known and feared consequence of anorectal surgery."	1.36	Topical mitomycin-C for the treatment of anal stricture. ( Beaunoyer, M; Mueller, CM; St-Vil, D, 2010)
"Mitomycin was used according to the senior surgeon's preference, and certainly not in a randomized fashion."	1.36	The use of adjunctive topical mitomycin in endoscopic congenital choanal atresia repair. ( Arbag, H; Azimov, A; Bozkurt, MK; Keles, B; Ozturk, K, 2010)
"Mitomycin C(MMC) was administered to 15 patients (58%) with needling being performed on 10 (38%) of these patients."	1.36	Deep sclerectomy with the Ex-PRESS X-200 implant for the surgical treatment of glaucoma. ( Bissig, A; Feusier, M; Mermoud, A; Roy, S, 2010)
" Based on the Wuerzburg bleb classification score (WBCS) for postoperative wound healing evaluation, 30 of these operations of group A (group B: n = 26) did not receive 5 FU postoperatively (controls), 67 (93) received up to 7 postoperative injections of 5 mg 5 FU (normal dosage group), and 72 (93) received more than 7 injections (high dosage group)."	1.36	[Corneal epitheliopathy following trabeculectomy with postoperative adjunctive 5-fluorouracil]. ( Geerling, G; Grehn, F; Klink, T; Reiter, C; Schultheiss, A; Wimmer, S, 2010)
"Mitomycin C (MMC) is a widely used agent for the adjuvant treatment of bladder tumors."	1.35	Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! ( Cek, M; Fazlioglu, A; Kurtulus, FO; Parlakkilic, O; Tandogdu, Z, 2009)
"No patients presented recurrence of the bleb leak or AMT-related complications during entire follow-up."	1.35	Long-term results of amniotic membrane transplantation-assisted bleb revision for leaking blebs. ( Fujioka, M; Nagai-Kusuhara, A; Nakamura, M; Negi, A, 2008)
" However, for moderate myopia and shallow depth, low dosing appears to be equally effective."	1.35	Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. ( Krueger, RR; Thornton, I; Xu, M, 2008)
"He consequently presented severe stenosis at the origin of the cervical esophagus that needed repeated balloon dilatations."	1.34	Topical application of mitomycin C in the treatment of esophageal and tracheobronchial stricture: a report of 2 cases. ( Adib, M; Daher, P; Georges, B; Georges, D; Riachy, E, 2007)
" Performing splenectomy and CDDP dosage for HIPEC >240 mg were proven to be independent risk factors for both G3-4 hyperamylasemia and POPF."	1.34	Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Antonucci, A; Baratti, D; Deraco, M; Gavazzi, C; Kusamura, S; Laterza, B; Oliva, GD; Younan, R, 2007)
"The overall recurrence rate was 178 (18."	1.33	Outcome of pterygium surgery: analysis over 14 years. ( Aasuri, MK; Bansal, AK; Fernandes, M; Gangopadhyay, N; Garg, P; Nutheti, R; Rao, GN; Sangwan, VS; Sridhar, MS, 2005)
"Mitomycin C treatment induces apoptosis of keratocytes and myofibroblasts, but the predominate effect in inhibiting or treating haze appears to be at the level of blocked replication of keratocytes or other progenitor cells of myofibroblasts."	1.33	Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. ( Gupta, PC; Mohan, RR; Netto, MV; Sharma, A; Sinha, S; Wilson, SE, 2006)
"Mitomycin C was placed in contact with the ablation zone for 75 seconds with an imbibed microsponge."	1.33	Comparison of laser epithelial keratomileusis with and without the use of mitomycin C. ( Argento, C; Cosentino, MJ; Ganly, M, 2006)
"Peritoneal carcinomatosis has been regarded as a lethal clinical entity."	1.32	Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. ( Cotte, E; François, Y; Freyer, G; Gilly, FN; Glehen, O; Isaac, S; Kwiatkowski, F; Osinsky, D; Sayag-Beaujard, AC; Trillet-Lenoir, V; Vignal, J, 2003)
"We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies."	1.32	Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure. ( Buchman, CA; Gomez-Marin, O; Jassir, D; Odabasi, O, 2003)
"Epidural fibrosis was evaluated histologically."	1.32	Mitomycin C in preventing spinal epidural fibrosis in a laminectomy model in rats. ( Ebel, H; Ernestus, RI; Klug, N; Lee, JY; Stenzel, W; Wedekind, C, 2004)
"To assess the efficacy of a bleb revision technique with regard to improvement in intraocular pressure (IOP) and visual acuity after hypotony maculopathy and to evaluate the influence of duration of hypotony on visual outcome."	1.32	Bleb revision for hypotony maculopathy after trabeculectomy. ( Bashford, KP; Shafranov, G; Shields, MB, 2004)
"The prognosis for intraabdominal carcinomatosis is poor with conventional treatments and modalities."	1.31	Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion. ( Chase, VA; Hunley, EK; Kuhn, JA; Loggie, BW; McCarty, TM; Sutton, SW; Yancey, LW, 2002)
"Mitomycin C has an adjunct effect in laser myringotomy in prolonging the patency rate of myringotomy on rats."	1.31	Topical use of mitomycin C in laser myringotomy: an experimental study in rats. ( Yucel, OT, 2000)
"Mitomycin C (MMC) is a cytotoxic agent that alkylates and crosslinks DNA and also inhibits fibroblast proliferation up to a few weeks."	1.31	An experimental study evaluating the effect of Mitomycin C on the prevention of postoperative intraabdominal adhesions. ( Alponat, A; Cubukçu, A; Erçin, C; Gönüllü, NN; Ozkan, S, 2001)
"In 3 dogs, recurrence was established after surgical lysis."	1.31	Prevention of anterior glottic restenosis in a canine model with topical mitomycin-C. ( Huang, S; Reinisch, L; Sanders, D; Spector, JE; Spector, NC; Werkhaven, JA, 2001)
"Mitomycin C (MMC) is an antineoplastic agent with an antiproliferative effect on fibroblasts."	1.31	Mitomycin C in sinus surgery: preliminary results in a rabbit model. ( Ahmarani, C; Péloquin, L; Rahal, A, 2001)
"Intraocular pressure was significantly lower and an avascular area was more frequent in eyes with oozing or leak than in eyes without (P <."	1.31	Late-onset transconjunctival oozing and point leak of aqueous humor from filtering bleb after trabeculectomy. ( Araie, M; Matsuo, H; Shirato, S; Suzuki, Y; Tomidokoro, A, 2002)
"Mitomycin C was administered intraoperatively in the dose of 0."	1.31	[Antimetabolites in glaucoma surgery--long-term results]. ( Ferková, S; Jakabovicová, E; Michalíková, L; Strmen, P, 2002)
"Astigmatism was reduced."	1.30	Single application mitomycin C in primary pterygium surgery. ( Pommerencke, C, 1998)
" A dose-response effect of the concentration of MMC and IOP levels is present, suggesting that the higher concentration leads to lower IOP values."	1.30	Three-year follow-up of trabeculectomies performed with different concentrations of mitomycin-C. ( Krieglstein, GK; Mietz, H, 1998)
"In these eyes, intraocular pressure is between 8 and 12 mmHg."	1.29	Treatment of postfiltration bleb leaks with autologous blood. ( Betchkal, J; Doyle, JW; Magauran, RG; Smith, MF, 1995)
"Mitomycin is an antibiotic with antineoplastic activity which inhibits fibroblast proliferation in the operative field in glaucoma filtering surgery."	1.29	Filtering surgery with mitomycin-C in uncomplicated (primary open angle) glaucoma. ( Doğan, H; Erkiliç, K; Karaküçük, S; Mirza, GE, 1994)
"Mitomycin C is a promising substance which improves substantially the prognosis of complicated cases of glaucoma."	1.29	[Initial experience with the use of mitomycin C in anti-glaucoma filtering surgery]. ( Liehneová, I; Rozsíval, P, 1994)
"Intraocular pressure was controlled successfully in 97."	1.29	Effects of topical mitomycin C on primary trabeculectomies and combined procedures. ( Costa, VP; Gandham, S; Moster, MR; Schmidt, CM; Smith, M; Wilson, RP, 1993)
"No recurrence was noted within the 1st year in the primary pterygium group, whereas recurrence was observed in 3/24 eyes that had been treated for recurrent pterygium, equivalent to a recurrence rate of 12."	1.28	Pterygium excision using 193-nm excimer laser smoothing and topical mitomycin C. ( Schnelle, B; Seiler, T; Wollensak, J, 1992)
"Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy."	1.28	Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989)
"The rates of recurrence (5% to 9%) and complications in eyes that had undergone excision and mitomycin C instillation were less than those in eyes that had had excision only."	1.28	Postoperative instillation of mitomycin C in the treatment of recurrent pterygium. ( Hayasaka, S; Noda, S; Setogawa, T; Yamamoto, Y, 1989)
"Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment."	1.27	Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983)
"Pseudomyxoma peritonei is an unusual malignancy arising from the goblet cells of the large bowel or appendix."	1.27	Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. ( Kern, K; Lack, E; Sugarbaker, PH, 1987)
"A new dosage form of activated carbon particles adsorbing mitomycin C (MMC-CH) was studied for its therapeutic effects on peritoneal dissemination in both animal experiments and preliminary clinical trials."	1.27	Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1988)

Research

Studies (619)

Authors

Clinical Trials (30)

Trial Overview

Trial Outcomes

Change in Intraocular Pressure

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (2.10)	18.7374
1990's	135 (21.81)	18.2507
2000's	214 (34.57)	29.6817
2010's	218 (35.22)	24.3611
2020's	39 (6.30)	2.80

Authors	Studies
Alagöz, N	1
Erdoğdu, E	1
Yaşar, T	1
Dooling, V	1
Lappas, A	2
Dietlein, TS	4
Gedde, SJ	10
Feuer, WJ	7
Lim, KS	2
Barton, K	5
Goyal, S	3
Ahmed, II	2
Brandt, JD	3
Mambo, Y	1
Higashide, T	6
Ohkubo, S	4
Udagawa, S	1
Yamashita, Y	1
Tsuchiya, S	1
Okayama, M	1
Wajima, R	1
Sugiyama, K	6
Cutolo, CA	4
Bonzano, C	4
Catti, C	3
Pizzorno, C	3
Bagnis, A	4
Traverso, CE	4
Iester, M	4
Vinod, K	1
Prum, BE	2
Upaphong, P	1
Pathanapitoon, K	1
Chaidaroon, W	1
Ley, D	1
Bridenne, M	1
Gottrand, F	2
Lemale, J	1
Hauser, B	1
Lachaux, A	1
Rebouissoux, L	1
Viala, J	1
Fayoux, P	1
Michaud, L	2
Khamar, M	1
Bhojwani, D	1
Patel, P	2
Vasavada, A	1
Somashekhar, SP	1
Yethadka, R	1
Kumar C, R	1
Ashwin, KR	1
Zaveri, S	1
Rauthan, A	1
Lu, PW	1
Fields, AC	1
Shabat, G	1
Bleday, R	1
Goldberg, JE	1
Irani, J	1
Stopfkuchen-Evans, M	1
Melnitchouk, N	1
Stahnke, T	1
Gajda-Derylo, B	1
Stachs, O	1
Guthoff, RF	1
Jünemann, A	1
Füllen, G	1
Camp, AS	1
Weinreb, RN	2
Elekonawo, FMK	1
van Eden, WJ	2
van der Plas, WY	1
Ewalds, RSG	1
de Jong, LAW	1
Bremers, AJA	1
Hemmer, PHJ	1
Kok, NFM	2
Kruijff, S	1
Aalbers, AGJ	2
de Reuver, PR	1
Li, XB	1
Ma, R	1
Ji, ZH	1
Lin, YL	1
Zhang, J	2
Yang, ZR	1
Chen, LF	1
Yan, FC	1
Li, Y	3
Chan, PP	1
Wong, LYN	1
Chan, TCY	1
Lai, G	1
Baig, N	1
Allam, RSHM	1
Raafat, KA	1
Abdel-Hamid, RM	1
Baratti, D	4
Sammartino, P	2
Kusamura, S	3
Deraco, M	3
Ansaloni, L	1
Asero, S	1
Baiocchi, G	1
Bagnoli, P	1
Cavaliere, D	1
Framarini, M	1
Cirocchi, R	1
Coccolini, F	1
Decian, F	1
Delrio, P	1
Sassaroli, C	1
De Simone, M	1
Robella, M	2
Vaira, M	1
Di Giorgio, A	2
Fagotti, A	1
Lorusso, D	1
Federici, O	2
Fiorentini, G	1
Fambrini, M	1
Scaringi, S	1
Garofalo, A	1
Valle, M	2
Gelmini, R	1
Cabry, F	1
Cautero, N	1
Sorrentino, L	1
Graziosi, L	1
Guaglio, M	1
Montenovo, M	1
Bartolini, V	1
Lippolis, PV	1
Macrì, A	1
Pasqual, EM	1
Roviello, F	1
Marrelli, D	1
Orsenigo, E	1
Sommariva, A	1
Chu, CK	1
Liebmann, JM	4
Cioffi, GA	1
Blumberg, DM	1
Al-Aswad, LA	1
Seth, PK	1
Sharma, S	1
Senthil, S	3
Halili, A	1
Kessel, L	1
Subhi, Y	1
Bach-Holm, D	2
Rolim-de-Moura, C	1
Esporcatte, BLB	1
F Netto, C	1
Paranhos, A	1
Gagrani, M	1
Garg, I	1
Ghate, D	2
Carboni, F	1
Zazza, S	1
Sperduti, I	1
Carlos de Oliveira, R	1
Wilson, SE	2
Olmos-Zuñiga, JR	1
Baltazares-Lipp, M	1
Hernández-Jiménez, C	1
Jasso-Victoria, R	1
Gaxiola-Gaxiola, M	1
Silva-Martínez, M	1
Iñiguez-García, MA	1
González-González, AI	1
Vázquez-Minero, JC	1
Luna-Flores, A	1
Solis-Alanis, N	1
Baltazares-Lipp, ME	1
Lee, GA	2
Craig, JE	1
Liu, L	3
Danesh-Meyer, HV	1
Lo Dico, R	1
Faron, M	1
Yonemura, Y	3
Glehen, O	3
Pocard, M	2
Sardi, A	1
Hübner, M	1
Liberale, G	1
Kartheuser, A	2
de Hingh, I	1
Sugarbaker, P	1
Ceelen, W	1
Moran, B	1
Quenet, F	2
Sideris, L	2
Goere, D	2
Limbert, M	1
Morris, D	1
Chen, X	1
Hong, Y	1
Zhang, C	1
Linehan, J	1
Schoenberg, M	1
Seltzer, E	1
Thacker, K	1
Smith, AB	1
Laspas, P	1
Wahl, J	2
Peters, H	1
Prokosch-Willing, V	3
Chronopoulos, P	1
Grehn, F	2
Pfeiffer, N	5
Hoffmann, EM	4
Chang, YM	1
Liang, CM	1
Weng, TH	1
Chien, KH	1
Lee, CH	3
Sayed, KM	1
Sanchez-Avila, RM	1
Uribe-Badillo, EE	1
Sanz, JF	1
Muruzabal, F	1
Jurado, N	1
Alfonso-Bartolozzi, B	1
Alfonso, JF	1
Baamonde, B	1
Anitua, E	1
Merayo-Lloves, J	1
Loaec, C	1
Guérin-Charbonnel, C	1
Vignaud, T	1
Paineau, J	1
Thibaudeau, E	1
Dumont, F	1
Dwivedi, R	1
Somerville, T	1
Cheeseman, R	1
Rogers, C	1
Batterbury, M	1
Choudhary, A	1
Zahid, A	1
Clarke, L	1
Carr, N	1
Chandrakumaran, K	1
Tzivanakis, A	1
Dayal, S	1
Mohamed, F	1
Cecil, T	1
Moran, BJ	1
Prabhu, A	1
Brandl, A	1
Wakama, S	1
Sako, S	1
Ishibashi, H	1
Mizumoto, A	1
Takao, N	1
Ichinose, M	1
Motoi, S	1
Liu, Y	2
Almobarak, FA	3
Alharbi, AH	3
Aljadaan, I	3
Aldhibi, H	1
Komae, K	1
Takamoto, M	1
Tanaka, R	1
Aihara, M	2
Ohtomo, K	1
Okinaga, K	1
Matsuda, J	1
Nakahara, H	1
Fujino, Y	1
Kaburaki, T	1
Eng, OS	1
Dumitra, S	1
O'Leary, M	1
Wakabayashi, M	1
Dellinger, TH	1
Han, ES	1
Lee, SJ	1
Benjamin Paz, I	1
Singh, G	1
Lee, B	1
Wirbelauer, C	1
Mertens, CN	1
Gollakota, S	1
Garudadri, CS	2
Mohamed, A	1
Sourial, MW	1
Richard, PO	1
Bettez, M	1
Jundi, M	1
Tu, LM	1
Xu, L	1
Tao, X	1
Li, Z	1
Xu, Y	1
Zhu, W	1
Xu, H	1
Pu, W	1
Xie, Y	1
Mu, G	1
Romera-Romero, P	1
Loscos-Arenas, J	1
Moll-Udina, A	1
Romanic-Bubalo, N	1
Castellvi-Manent, J	1
Valldeperas, X	2
Tran, AQ	1
Hoeppner, C	1
Venkateswaran, N	1
Choi, DS	1
Lee, WW	1
Scotto, R	1
Quist, MS	1
Brown, N	1
Bicket, AK	1
Herndon, LW	3
Mercieca, K	2
Drury, B	1
Bhargava, A	1
Fenerty, C	1
Bandeira E Silva, F	1
Hazarbassanov, RM	1
Martines, E	1
Güell, JL	1
Hofling-Lima, AL	1
Chen, PP	4
Heuer, DK	2
Singh, K	7
Wright, MM	3
Schiffman, JC	5
Shi, W	4
Woensdregt, K	1
Huitema, ADR	1
Boot, H	2
Kozman, MA	1
Fisher, OM	1
Rebolledo, BJ	1
Parikh, R	1
Valle, SJ	1
Arrowaili, A	1
Alzahrani, N	1
Liauw, W	1
Morris, DL	2
Jo, SH	1
Seo, JH	1
Pathak-Ray, V	1
Choudhari, N	1
Garris, WJ	1
Le, C	2
Zurakowski, D	2
Ayyala, RS	4
Yung, ES	1
Moster, MR	8
Sanvicente, C	1
Pluta, J	1
Rahmatnejad, K	1
Patel, AS	1
Williams, A	1
Abramowitz, B	1
Katz, LJ	2
Pro, M	1
Coelho, LM	1
Sieiro, RO	1
Klezlova, A	1
Liebezeit, S	1
Gericke, A	1
Lamparter, J	1
Ul Hassan, SN	1
Toshev, AP	1
Ahmed, IIK	1
Brandt, J	1
Chen, HJ	1
Lin, C	1
Chen, YH	1
Hoang, TKH	1
Kim, YK	1
Jeoung, JW	1
Park, KH	3
Thakur, SKD	1
Shaheer, M	1
Amjad, A	1
Ahmed, N	1
Dave, TV	1
Ezeanosike, E	1
Naik, MN	1
Ali, MJ	3
Mehlan, J	1
Linke, SJ	1
Skevas, C	1
Steinberg, J	1
Giannakakis, K	1
Katz, T	1
Davidson, KR	1
Elmasri, M	1
Wahidi, MM	1
Shofer, SL	1
Cheng, GZ	1
Mahmood, K	1
Abdalrahman, O	1
Rodriguez, AE	1
Alio Del Barrio, JL	1
Alio, JL	1
Nishino, T	1
Sakaguchi, K	1
Yamada, Y	1
Moeller, KL	1
Rajendrababu, S	1
Shroff, S	1
Patil, SV	1
Uduman, MS	1
Vardhan, A	1
Krishnadas, SR	1
Artini, W	1
Bani, AP	1
Kozobolis, V	1
Kalogianni, E	1
Sideroudi, H	1
Swann, FB	1
Singh, S	1
Blake, D	1
John, V	1
Fullerton, M	1
Margo, C	1
Zhang, Z	2
Muddasani, N	1
Wall, J	1
Satija, C	1
Greenberg, E	1
Mancera, N	1
Arranz-Marquez, E	1
Katsanos, A	1
Kozobolis, VP	2
Konstas, AGP	1
Teus, MA	4
Wadke, V	1
Lingam, V	1
George, R	1
George, AE	1
Ganesh, SK	1
Biswas, J	1
Balekudaru, S	1
Nakakura, S	1
Noguchi, A	1
Tanabe, H	1
Tabuchi, H	1
Asaoka, R	1
Kiuchi, Y	3
Gupta, V	1
Shaikh, NF	1
Gupta, S	1
Yuasa, Y	1
Sugimoto, Y	2
Hirooka, K	1
Narsani, AK	1
Nagdev, PR	1
Memon, MN	1
Sui, T	2
Hong, X	1
Wu, X	2
Cao, X	2
Lee, S	3
Go, J	1
Rhiu, S	2
Stulting, RD	3
Lee, M	2
Jang, S	1
Kim, HJ	1
Chung, ES	1
Kim, S	1
Seo, KY	3
Shin, HY	1
Kim, MS	1
Chung, SK	3
Chua, TC	1
Quinn, LE	1
Zhao, J	1
Rosentreter, A	2
Ono, T	2
Yuki, K	2
Ozeki, N	1
Shiba, D	2
Tsubota, K	2
Hofmeister, EM	2
Bishop, FM	2
Kaupp, SE	2
Schallhorn, SC	3
Zarbin, MA	1
Young, AL	3
Ho, M	1
Jhanji, V	1
Cheng, LL	3
Kheirkhah, A	3
Nazari, R	2
Safi, H	1
Ghassemi, H	2
Behrouz, MJ	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device[NCT02016898]	Phase 2	100 participants (Actual)	Interventional	2014-03-31	Completed
Primary Tube Versus Trabeculectomy Study[NCT00666237]	Phase 4	242 participants (Actual)	Interventional	2008-04-01	Completed
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951]	Phase 2/Phase 3	358 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Comparing the Effectiveness of Phacoemulsification + ECP Laser and Phacoemulsification Alone for the Treatment of Open Angle Glaucoma in Patients With Cataract - a Randomised Controlled Trial[NCT04295122]	Phase 4	160 participants (Anticipated)	Interventional	2020-03-15	Not yet recruiting
Glycerin-Preserved, Human-Donor, Corneoscleral Patch Grafts for Glaucoma Drainage Devices[NCT04949347]		100 participants (Actual)	Observational	2017-02-22	Completed
Deep Sclerectomy vs Xen in Solo Procedure: Comparative Study, Efficacy and Safety Profile[NCT05201378]		282 participants (Actual)	Observational	2021-07-15	Completed
[NCT02665884]		40 participants (Anticipated)	Observational	2016-02-29	Not yet recruiting
A Multi Center Study Comparing the Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma[NCT00444080]		120 participants (Actual)	Interventional	2006-10-31	Completed
Prospective Study on Ex-PRESS Implantation Combined With Phacoemulsification in Primary Angle-closure Glaucoma[NCT03323138]		40 participants (Anticipated)	Interventional	2012-07-01	Recruiting
Phaco-UCP; Combined Phacoemulsification and Ultrasound Ciliary Plasty Versus Phacoemulsification Alone for Management of Coexisting Cataract and Open Angle Glaucoma[NCT04430647]		61 participants (Actual)	Interventional	2018-03-01	Completed
Comparison of Effectiveness and Safety of Eye Fixation Types During Combined Glaucoma Procedures[NCT03797846]		41 participants (Actual)	Interventional	2018-01-01	Completed
Comparison of Surgical Treatment Options for Primary Congenital and Developmental Glaucomas[NCT04647929]		0 participants (Actual)	Interventional	2020-12-01	Withdrawn (stopped due to Funding for the study could not be found.)
Effect of WeChat Application Combined Phone Reminder on Follow-up Adherence Improvement in Congenital Ectopia Lentis Patients : A Randomized Controlled Trial[NCT05628129]		104 participants (Anticipated)	Interventional	2022-12-05	Recruiting
A Randomized Controlled Trail to Determine the Impact of a SMS Reminder Associated With Free Eye Drops on Follow-up Adherence After Trabeculectomy Surgery in Rural China[NCT02328456]		209 participants (Actual)	Interventional	2014-12-31	Completed
Comparison of Combined Phacotrabeculectomy and Trabeculectomy Only in the Treatment of Primary Angle-closure Glaucoma[NCT01298635]		31 participants (Actual)	Interventional	2005-01-31	Completed
Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Chinese Primary Angle Closure Glaucoma[NCT02964676]		246 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Tube Versus Trabeculectomy (TVT) Study[NCT00306852]		212 participants (Actual)	Interventional	1999-10-31	Completed
Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Primary Open Angle Glaucoma: a Three-year Comparative Study[NCT01633775]		100 participants (Actual)	Observational	2007-12-31	Completed
Comparison of ExPress Implantation Versus Partial Deep Sclerectomy Combined With ExPress Implantation With Simultaneously Phacoemulsification[NCT03800589]		186 participants (Actual)	Interventional	2010-12-01	Completed
Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation - a Prospective Cohort Study at the Ophthalmology Department Klinikum Klagenfurt[NCT06174324]		100 participants (Anticipated)	Observational	2021-10-12	Recruiting
Two Years Follow up of Corneal Cor Cross-linking and Refractive Surface Ablation in Patients With Asymmetric Corneal Topography[NCT02943967]		44 participants (Actual)	Interventional	2010-01-31	Completed
IOP Reduction and Complications of Polymethyl Methacrylate Glaucoma Drainage Device on Glaucoma Patient[NCT04052165]		150 participants (Actual)	Interventional	2015-07-01	Completed
A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus[NCT04584125]		216 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy[NCT00695747]		95 participants (Actual)	Interventional	1998-01-31	Completed
Evaluation of Macular Thickness in Patients With Glaucoma in Use of Topical Prostaglandin Analogue Undergoing Trabeculectomy With Mitomycin C[NCT06000280]		37 participants (Actual)	Interventional	2021-01-04	Completed
Modified Trabeculectomy With an Extended Subscleral Tunnel Versus Conventional Trabeculectomy for Management of Primary Open Angle Glaucoma (POAG)[NCT03480711]		40 participants (Actual)	Interventional	2018-07-10	Completed
Surgical and Refractive Outcomes of Combined Phaco-ExPress Versus Phacotrabeculectomy - 6 Months Results.[NCT04335825]		81 participants (Actual)	Interventional	2016-01-01	Completed
A Prospective, Multicentral, Open-label, Randomized, Controlled Clinical Trial to Investigation the Value of Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer[NCT02745509]		508 participants (Actual)	Interventional	2016-03-31	Completed
Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding[NCT00539877]	Phase 1	17 participants (Actual)	Interventional	2004-10-31	Completed
Intermediate Term Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin c in Trabeculectomy Surgery.[NCT00346489]	Phase 4	70 participants	Interventional	2004-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To assess final intraocular pressure lowering between patients who receive mitomycin-C using a sponge versus irrigation (NCT02016898)
Timeframe: post-operative day 1 to month 6

Complication Rates

Intervention	mmHg (millimeters of mercury) (Mean)
Sponge Placement of Mitomycin-C	-8.4
Irrigation Placement of MMC	-8.2

To assess complication rates between patients who receive mitomycin-C using a sponge versus irrigation (NCT02016898)
Timeframe: post-operative day 1 to month 6

Reoperation for Glaucoma

Intervention	Participants (Count of Participants)
Sponge Placement of Mitomycin-C	29
Irrigation Placement of MMC	28

The number of participants requiring reoperation for glaucoma will be reported (NCT00666237)
Timeframe: Up to 5 years

Intraocular Pressure

Intervention	Participants (Count of Participants)
Tube Shunt Surgery Group	21
Trabeculectomy With Mitomycin C	12

Intraocular pressure will be reported in mmHg and measured using Goldmann applanation tonometry or a Tono-Pen. (NCT00666237)
Timeframe: At baseline, At 1 year, At 18 months, At 2 years, At 3 years, At 4 years, At 5 years

Number of Glaucoma Medications

Intervention	mmHg (Mean)
	Intraocular Pressure: Baseline	Intraocular Pressure: 1 year	Intraocular Pressure: 18 months	Intraocular Pressure: 2 years	Intraocular Pressure: 3 years	Intraocular Pressure: 4 years	Intraocular Pressure: 5 years
Trabeculectomy With Mitomycin C	23.9	12.4	12.8	12.9	12.1	13.5	13.0
Tube Shunt Surgery Group	23.3	13.8	13.5	13.6	13.9	13.5	13.4

The need for supplemental glaucoma medications will be reported as the number of glaucoma medications used (NCT00666237)
Timeframe: At Baseline, At 1 year, At 18 months, At 2 years, At 3 years, At 4 years, At 5 years

Number of Participants With Reported Postoperative Complications

Intervention	glaucoma medications used (Mean)
	Baseline	1 year	18 months	2 years	3 years	4 years	5 years
Trabeculectomy With Mitomycin C	3.2	0.9	0.8	1.0	1.2	1.3	1.3
Tube Shunt Surgery Group	3.1	2.1	2.1	2.2	2.1	2.3	2.2

Number of participants with early and late postoperative complications will be reported as per treating physician assessment (NCT00666237)
Timeframe: Up to 5 years

Number of Participants With Surgical Failure

Intervention	Participants (Count of Participants)
	Early Postoperative Complications	Late Postoperative Complications
Trabeculectomy With Mitomycin C	40	32
Tube Shunt Surgery Group	24	27

"Surgical failure is defined as:~Inadequate Intraocular Pressure (IOP) Reduction (IOP > 21 mmHg or reduced < 20% below baseline on 2 consecutive follow-up visits after 3 months)~Reoperation for glaucoma~Persistent hypotony (IOP ≤ 5 mmHg on 2 consecutive visits after 3 months)~Loss of light perception vision" (NCT00666237)
Timeframe: Up to 5 years

Visual Acuity as Measured Using EDTRS Chart

Intervention	Participants (Count of Participants)
	Inadequate IOP reduction	Reoperation for Glaucoma	Loss of light perception vision	Persistent Hypotony
Trabeculectomy With Mitomycin C	23	9	1	5
Tube Shunt Surgery Group	31	18	0	0

Visual acuity will be reported as the number of correctly identified letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) chart. Total score ranges from 0-100 with the higher score indicating better visual acuity. (NCT00666237)
Timeframe: At baseline, At 5 years

Visual Acuity Using a Snellen Chart

Intervention	letters (Mean)
	Baseline	5 years
Trabeculectomy With Mitomycin C	73	66
Tube Shunt Surgery Group	73	69

Visual acuity will be measured using a Snellen chart on logMAR (Logarithm of Minimal Angle of Resolution) scale. Letter-by letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20. (NCT00666237)
Timeframe: At Baseline, At 5 years

Efficacy - The Number of Participants With Qualified and Complete Success

Intervention	logMAR (Mean)
	Baseline	5 years
Trabeculectomy With Mitomycin C	0.25	0.42
Tube Shunt Surgery Group	0.20	0.30

The secondary effectiveness measure will be qualified and complete success rate defined as IOP≤18mmHg with or without medications in the test group as compared to qualified and complete success rate in the concurrent control group at 24 month (NCT00444080)
Timeframe: 24 months

Medications

Intervention	participants (Number)
Control Arm	48
Treatment Arm	49

(NCT00444080)
Timeframe: assessed at 1d, 1w, 1m, 3m, 6m, 12m, 18m, 24m; 24 months reported

Postoperative Intraocular Pressure

Intervention	number of medications (Mean)
Control Arm	0.7
Treatment Arm	0.9

Mean postoperative intraocular pressure (NCT00444080)
Timeframe: assessed at 1d, 1w, 1m, 3m, 6m, 12m, 18m, 24m. 24 months reported

Safety - Incidence of Adverse Events

Intervention	mmHg (Mean)
Control Arm	14.6
Treatment Arm	14.7

Comparison of the incidence of all adverse events that occur during the intra-operative and postoperative periods between the two study arms. More than 1 complication may have occurred in the same subject. (NCT00444080)
Timeframe: 24 months

Change in Intraocular Pressure

Intervention	complications (Number)
Control Arm	25
Treatment Arm	11

The data value from the Baseline visit and 5 year follow-up visit were combined. Specifically, values were calculated by subtracting the 5 Year Intraocular Pressure from the Baseline Intraocular Pressure. (NCT00306852)
Timeframe: Baseline to 5 years

Failure Rate

Intervention	mm Hg (Mean)
Trabeculectomy	12.6
Implant	14.4

Failure was prospectively defined as IOP greater than 21 mm Hg or less than 20 percent reduction below baseline on 2 consecutive follow-up visits after 3 months, IOP less than or equal to 5 mm Hg on 2 consecutive follow-up visits after 3 months, re-operation for glaucoma, or loss of light perception vision. (NCT00306852)
Timeframe: 5 years

Need for Supplemental Medical Therapy

Intervention	percentage of participants (Number)
Trabeculectomy	46.9
Implant	29.8

The number of supplemental glaucoma medications required in the Implant Group and Trabeculectomy Group at 5 years (NCT00306852)
Timeframe: 5 years

Reoperations for Glaucoma

Intervention	number of medications (Mean)
Trabeculectomy	1.2
Implant	1.4

Reoperations for glaucoma was defined as additional glaucoma surgery requiring a return to the operating room. (NCT00306852)
Timeframe: 5 years

Rate of Complications

Intervention	participants (Number)
Trabeculectomy	15
Implant	20

Complications associated with both surgical procedures (NCT00306852)
Timeframe: 5 years

Visual Acuity

Intervention	participants (Number)
	EARLY POSTOPERATIVE COMPLICATIONS	LATE POSTOPERATIVE COMPLICATIONS
Implant	33	36
Trabeculectomy	39	38

Visual acuity was measured by the total number of letters read (correctly) using a ETDRS eye chart (NCT00306852)
Timeframe: 5 years

mitomycin and Postoperative Complications

Research Excerpts

Research

Studies (619)

Authors

Clinical Trials (30)

Trial Overview

Trial Outcomes

Change in Intraocular Pressure

Complication Rates

Reoperation for Glaucoma

Intraocular Pressure

Number of Glaucoma Medications

Number of Participants With Reported Postoperative Complications

Number of Participants With Surgical Failure

Visual Acuity as Measured Using EDTRS Chart

Visual Acuity Using a Snellen Chart

Efficacy - The Number of Participants With Qualified and Complete Success

Medications

Postoperative Intraocular Pressure

Safety - Incidence of Adverse Events

Change in Intraocular Pressure

Failure Rate

Need for Supplemental Medical Therapy

Reoperations for Glaucoma

Rate of Complications

Visual Acuity

Reviews

Trials

Other Studies

Intervention	Letters (Mean)
	PATIENTS WITH COMPLICATIONS	PATIENTS WITHOUT COMPLICATIONS
Implant	33	46
Trabeculectomy	56	44

Article	Year
Results from the Primary Tube Versus Trabeculectomy Study and translation to clinical practice. Current opinion in ophthalmology, 2023, Mar-01, Volume: 34, Issue:2 Topics: Adolescent; Follow-Up Studies; Glaucoma; Glaucoma Drainage Implants; Humans; Intraocular Pressure; M	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Needling after trabeculectomy - does augmentation by anti-metabolites provide better outcomes and is Mitomycin C better than 5-Fluoruracil? A systematic review with network meta-analyses. Acta ophthalmologica, 2020, Volume: 98, Issue:7 Topics: Fluorouracil; Glaucoma; Humans; Immunosuppressive Agents; Intraocular Pressure; Mitomycin; Network M	2020
Surgical interventions for primary congenital glaucoma. The Cochrane database of systematic reviews, 2020, 08-25, Volume: 8 Topics: Child, Preschool; Glaucoma; Glaucoma Drainage Implants; Humans; Hyphema; Infant; Infant, Newborn; In	2020
Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK. Experimental eye research, 2020, Volume: 200 Topics: Alkylating Agents; Corneal Opacity; Corneal Stroma; Fibrosis; Humans; Lasers, Excimer; Mitomycin; My	2020
Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma. Urology, 2021, Volume: 147 Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Fever; Humans; Incidence; Kidney	2021
Mitomycin C for the prevention of corneal haze in photorefractive keratectomy: a meta-analysis and trial sequential analysis. Acta ophthalmologica, 2021, Volume: 99, Issue:6 Topics: Corneal Opacity; Cross-Linking Reagents; Humans; Mitomycin; Myopia; Photorefractive Keratectomy; Pos	2021
[Role of Intraoperative Indirect Channelography in Glaucoma Stent Implantation]. Klinische Monatsblatter fur Augenheilkunde, 2017, Volume: 234, Issue:11 Topics: Administration, Ophthalmic; Aged, 80 and over; Bevacizumab; Combined Modality Therapy; Female; Fluor	2017
Complications of cosmetic eye whitening. Cutis, 2017, Volume: 100, Issue:3 Topics: Alkylating Agents; Conjunctival Diseases; Cosmetic Techniques; Humans; Mitomycin; Ophthalmic Solutio	2017
Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials. Ophthalmic research, 2018, Volume: 59, Issue:3 Topics: Administration, Topical; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Bevacizumab; Glaucoma	2018
A Critical Overview of the Biological Effects of Mitomycin C Application on the Cornea Following Refractive Surgery. Advances in therapy, 2019, Volume: 36, Issue:4 Topics: Antibiotics, Antineoplastic; Cornea; Corneal Diseases; Corneal Surgery, Laser; Humans; Mitomycin; Po	2019
Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA ophthalmology, 2013, Volume: 131, Issue:12 Topics: Antimetabolites; Databases, Factual; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pr	2013
[The mechanism and progress of topical application of mitomycin C as an adjunctive therapy for benign airway stenosis]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2013, Volume: 36, Issue:8 Topics: Administration, Inhalation; Administration, Topical; Airway Obstruction; Animals; Bronchoscopy; Cica	2013
Surgical interventions for primary congenital glaucoma. The Cochrane database of systematic reviews, 2015, Jan-30, Volume: 1 Topics: Child, Preschool; Glaucoma; Glaucoma Drainage Implants; Humans; Infant; Infant, Newborn; Mitomycin;	2015
Mitomycin-C in corneal surface excimer laser ablation techniques: a report by the American Academy of Ophthalmology. Ophthalmology, 2015, Volume: 122, Issue:6 Topics: Academies and Institutes; Alkylating Agents; Combined Modality Therapy; Cornea; Corneal Surgery, Las	2015
Mitomycin-C in dacryocystorhinostomy: From experimentation to implementation and the road ahead: A review. Indian journal of ophthalmology, 2015, Volume: 63, Issue:4 Topics: Dacryocystorhinostomy; Endoscopy; Humans; Lacrimal Duct Obstruction; Mitomycin; Nucleic Acid Synthes	2015
Catheter-based transarterial therapies for hepatocellular cancer. Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Doxorub	2015
Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with mitomycin C in treatment of open-angle glaucoma: a meta-analysis. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2009, Volume: 44, Issue:1 Topics: Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Databases, Factual; Filterin	2009
Efficacy and tolerability of nonpenetrating filtering surgery in the treatment of open-angle glaucoma: a meta-analysis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2010, Volume: 224, Issue:3 Topics: Combined Modality Therapy; Glaucoma, Open-Angle; Humans; Mitomycin; Postoperative Complications; Ran	2010
Review of results from the Tube Versus Trabeculectomy Study. Current opinion in ophthalmology, 2010, Volume: 21, Issue:2 Topics: Alkylating Agents; Combined Modality Therapy; Glaucoma; Glaucoma Drainage Implants; Humans; Intraocu	2010
[Conjunctival tumours in elderly patients]. Klinische Monatsblatter fur Augenheilkunde, 2010, Volume: 227, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Combined	2010
Postoperative prevention and treatment of complications after sinus surgery. Otolaryngologic clinics of North America, 2010, Volume: 43, Issue:4 Topics: Anti-Bacterial Agents; Antifungal Agents; Cross-Linking Reagents; Debridement; Endoscopy; Gelatin Sp	2010
Clinical findings and treatments of granular corneal dystrophy type 2 (avellino corneal dystrophy): a review of the literature. Eye & contact lens, 2010, Volume: 36, Issue:5 Topics: Chromosomes, Human, Pair 5; Contraindications; Cornea; Corneal Dystrophies, Hereditary; Corneal Tran	2010
Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery. American journal of ophthalmology, 2011, Volume: 152, Issue:1 Topics: Alkylating Agents; Angiogenesis Inhibitors; Filtering Surgery; Fluorouracil; Glaucoma, Open-Angle; H	2011
Interpretation and misinterpretation of results from the tube versus trabeculectomy study. International ophthalmology clinics, 2011,Summer, Volume: 51, Issue:3 Topics: Follow-Up Studies; Glaucoma; Glaucoma Drainage Implants; Humans; Incidence; Intraocular Pressure; In	2011
Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU international, 2012, Volume: 110, Issue:5 Topics: Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Chemotherapy, Adjuva	2012
[Modulation of wound healing in filtration surgery for glaucoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2003, Volume: 100, Issue:4 Topics: Adolescent; Adult; Age Factors; Alkylating Agents; Animals; Antimetabolites; Child; Filtering Surger	2003
[Dacryocystorhinostomy - state of the art, indications, results]. Laryngo- rhino- otologie, 2004, Volume: 83, Issue:1 Topics: Dacryocystorhinostomy; Endoscopy; Follow-Up Studies; Humans; Lacrimal Duct Obstruction; Laser Therap	2004
Use of mitomycin C in the pediatric airway. Current opinion in otolaryngology & head and neck surgery, 2004, Volume: 12, Issue:6 Topics: Animals; Child; Granulation Tissue; Humans; Mitomycin; Nucleic Acid Synthesis Inhibitors; Plastic Su	2004
Mitomycin: clinical applications in ophthalmic practice. Drugs, 2006, Volume: 66, Issue:3 Topics: Antibiotics, Antineoplastic; Cicatrix; Conjunctival Neoplasms; Glaucoma; Humans; Melanoma; Mitomycin	2006
Epi-LASIK update: overview of techniques and patient management. International ophthalmology clinics, 2006,Summer, Volume: 46, Issue:3 Topics: Adult; Epithelium, Corneal; Female; Humans; Keratomileusis, Laser In Situ; Male; Mitomycin; Nucleic	2006
[Wound healing modulation in glaucoma surgery]. Journal francais d'ophtalmologie, 2007, Volume: 30, Issue:6 Topics: Adult; Animals; Cataract Extraction; Child; Cicatrix; Eye Diseases; Filtering Surgery; Fluorouracil;	2007
Surface ablation. International ophthalmology clinics, 2008,Winter, Volume: 48, Issue:1 Topics: Alkylating Agents; Corneal Stroma; Humans; Keratomileusis, Laser In Situ; Lasers, Excimer; Mitomycin	2008
[Pulmonary toxicity of antineoplastic agents--with special reference to current findings on pulmonary toxicity of bleomycin]. Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:9 Topics: Animals; Antineoplastic Agents; Bleomycin; Busulfan; Cyclophosphamide; Humans; Lung; Mercaptopurine;	1982
Mitomycin C primary trabeculectomy in primary glaucoma of white patients. Journal of glaucoma, 1997, Volume: 6, Issue:5 Topics: Antimetabolites; Cataract; Disease Progression; Glaucoma; Humans; Intraocular Pressure; Intraoperati	1997
A major review of antimetabolites in glaucoma therapy. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1999, Volume: 213, Issue:4 Topics: Antimetabolites; Cytarabine; Filtering Surgery; Fluorouracil; Glaucoma; Humans; Mitomycin; Ophthalmi	1999
[The use of antimetabolites in the treatment of glaucoma]. Oftalmologia (Bucharest, Romania : 1990), 1999, Volume: 48, Issue:3 Topics: Antimetabolites; Chemotherapy, Adjuvant; Fluorouracil; Glaucoma; Humans; Intraoperative Care; Mitomy	1999
Combined surgery in the treatment of patients with cataract and primary open-angle glaucoma. Journal of cataract and refractive surgery, 2001, Volume: 27, Issue:11 Topics: Cataract; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Mitomy	2001
Acute scleral thinning after pterygium excision with intraoperative mitomycin C: a case report of scleral dellen after bare sclera technique and review of the literature. Cornea, 2002, Volume: 21, Issue:2 Topics: Acute Disease; Humans; Intraoperative Period; Lactose; Lubrication; Male; Methylcellulose; Middle Ag	2002
[Use of drugs inhibiting fibrosis after trabeculectomy]. Harefuah, 1992, Nov-15, Volume: 123, Issue:10 Topics: Adrenal Cortex Hormones; Aminopropionitrile; Fibrosis; Fluorouracil; Humans; Mitomycin; Postoperativ	1992